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   The growing burden of diabetes (DM) in many countries is contributing to sustain high incidence 
rates of tuberculosis (TB). The association between DM and TB results in poor treatment outcomes, 
posing a threat to TB control. Drug-induced liver injury (DILI) due to TB drugs is a major concern.  
There is currently limited evidence on the effect of DM on TB DILI.   
Aim and Objectives 
   The aim was to determine whether DILI is more frequent amongst TB patients with DM than 
without it; and to identify co-factors predictive of an increased risk of DM-associated DILI. The   
objectives were to undertake a case-control study of TB patients with and without DILI to determine 
the effect of DM as a risk factor for DILI; and to further investigate predictors of DILI in patients with 
DM and any co-factors associated with increased risk.    
Methods 
    A case control study. The cases were all TB patients with DILI due to the use of rifampicin, 
isoniazid, pyrazinamide and ethambutol (RHZE) who were registered on the Information System for 
Special Tuberculosis Treatments (SITETB) from January 2013 until July 2017 in Porto Alegre, Brazil. 
The controls were TB patients on RHZE who did not develop DILI during the same period. The 
exposure variables of interest were DM, age, sex, alcohol misuse, HIV, HCV, HBV, concomitant 
hepatotoxic drugs, other liver diseases, TB site and time to DILI.  
Results 
    The analysis showed that DM, sex, taking other hepatotoxic drugs and having only 
extrapulmonary TB (EPTB) were not associated with increased odds of DILI. Age over 50 years old, 
HIV infection, HCV infection and having both pulmonary TB (PTB) and EPTB were shown to increase 
the odds of having TB DILI. Hepatitis C infection acted as effect modifier on the effect of DM on DILI, 









    This study confirms evidence from the literature on the association between DILI and well-known 
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DOES DIABETES MELLITUS COMORBIDITY INCREASE THE RISK OF DRUG-INDUCED LIVER 
INJURY DURING TUBERCULOSIS TREATMENT? 
 
CHAPTER 1  -  INTRODUCTION  
 
1.1   Global epidemiology of tuberculosis 
    In 1993, the World Health Organization (WHO) declared tuberculosis (TB) a global health 
emergency (1). Almost thirty years later, it remains a significant public health problem as a major 
cause of morbidity and mortality worldwide despite efforts at its control. Worldwide, tuberculosis 
is one of the top 10 causes of death (2). Ending the global TB epidemic by 2030 is among the health 
targets of the newly adopted Sustainable Development Goals (SDG) (3). In 2017, 10 million people 
fell ill with TB and 1.6 million died from the disease, including 0.3 million among Human 
Immunodeficiency Virus (HIV) patients (2). Over 95% of the cases and deaths occur in low-and 
middle-income countries (3). In 2017, the largest number (62%) of incident TB cases occurred in the 
South-East Asia and Western Pacific regions, followed by the African region, with 25% of incident 
cases. In that same year, two thirds of incident TB cases occurred in India, China, Indonesia, the 
Philippines, Pakistan, Nigeria, Bangladesh and South Africa, all of which are among the 30 high TB 
burden countries (2).  Globally, TB incidence has fallen by an average of 1.5% per year since 2000, 
remained 1.5% from 2014 to 2015 (3) and is now declining at about 2% per year (2).  
    One of the targets of the Millenium Development Goals was to stop and begin to reverse TB 
incidence by 2015. However, this rate of decline of 2% per year needs to accelerate in order for the 
needed milestones to be reached. The WHO End TB Strategy, adopted by the World Health 
Assembly in 2014, aims to end the global TB epidemic by decreasing the number of TB deaths by 
90%, by reducing new TB cases by 80% between 2015 and 2030, and by eliminating the TB-related 
financial burden to families (2). Ending the TB epidemic by 2030 is one of the health targets of the 
most recently adopted by the SDG. Additionally, WHO has set up a new target for 2035: a 95% 
reduction in deaths and a 90% decline in TB incidence (2).  
    In Brazil, TB remains a major public health concern, with an incidence rate of 34/100.000 





incidence rate decreased from 42.8 to 35/100.000 population and its mortality rate decreased from 
3.1 to 2.2/100.000 population from 2001 to 2016 (4). In 2017, the state of Rio Grande do Sul 
presented an incidence rate of 41/100.000 population and in its capital, Porto Alegre, the incidence 
rate was a little over 80/100.000 population (4).  
    It has been estimated that approximately 1.7 billion persons were infected with Mycobacterium 
tuberculosis (Mtb) globally in 2014, nearly 25% of the world population (5). From this reservoir of 
1.7 billion people with latent TB infection (LTBI), approximately 170 million will develop active TB 
during their lifetime, more than 80% of whom will be in the pulmonary form and, therefore, 
infectious to others (6). Individuals with active TB can infect 10 – 15 other people per year. Without 
treatment, 45% of HIV negative patients and nearly all HIV positive patients will be dead in 2 years 
(2).    
 
1.2   Risk factors for tuberculosis 
    An impaired immunological status has been acknowledged as an important factor determining TB 
control. The co-infection with HIV and Mtb is the strongest risk factor for both immediate and 
delayed progression from latent infection to active TB (7, 8), but there are other clinical conditions 
also associated with that, such as malnutrition, drug and alcohol abuse, aging, immunosuppressive 
therapy, and coexistent medical conditions such as diabetes mellitus (DM), chronic renal disease, 
silicosis, jejuno-ileal bypass, subtotal gastrectomy, cancer (7, 8) and, more recently identified, 
smoking (7, 9-11).  
 
1.3   Global epidemiology of DM 
    The prevalence of DM is rapidly increasing and that is a global epidemic (12). Aging, changes in 
life style, socio-economic factors and population growth have led to an increasing DM prevalence, 
particularly type 2 DM (13). According to the International Diabetes Federation Atlas (14), one in 11 
adults have DM, and 46.5% of adults with DM are undiagnosed. Three quarters of people with DM 
live in low and middle income countries (14). By 2040, one adult in 10 will have DM. In South and 
Central America, 9.4% (8.0% – 11.3%) of the adult population have DM. Of these, 39% are 





the globe. According to estimates, India and China are and will continue to be the two countries 
with the greatest burden of the disease. Up to 80% of patients with DM live in low income countries 
(15) and 70% of patients with DM live in countries where TB is endemic. Indonesia, with the third 
highest burden of TB in the world, has the fourth highest number of individuals with DM (16).  Other 
countries in similar situation are Peru and Russia (17).  In Central and South Americas, Brazil has the 
highest number of people with DM: 14.3 million. In 2015, 247.500 adults died as a result of DM in 
Central and South Americas and over half of the deaths occurred in Brazil (14). 
    It has been estimated by WHO that the global prevalence of DM among adults has risen from 4.7% 
in 1980 to 8.5% in 2014. The number of individuals with DM has risen from 108 million in 1980 to 
422 million. According to the Global Report on DM, in 2016, an estimated 1.6 million deaths were 
directly caused by DM, rendering it to be the 7th leading cause of death in that year (18). Likewise, 
it has been projected by WHO that DM will be the 7th leading cause of death in 2030. In Brazil, 6% 
of total deaths in 2016 were caused by DM. In the same year, the total prevalence of DM was 8.1%, 
being 7.4% in males and 8.8% in females (18). It has been estimated that 50% of the population with 
DM are undiagnosed (10) and low and middle-income countries account for 88% of all the 
premature mortality due to DM (10). According to the Brazilian Diabetes Association, there are 
currently over 13 million people with DM, 6.9% of the Brazilian population (19). 
 
1.4   DM and TB   
1.4.1   DM and active TB 
    Diabetes increases the risk of infection in general. The killing of Mtb by drugs requires a properly 
functioning immune system and although all the precise mechanisms are still not entirely known 
(12, 20), DM is known to cause immune dysfunction and suppression of the cellular immunity (21, 
22). Studies on the effect of DM on both the innate and adaptive immune response to Mtb have 
shown that the most consistent (although not universal) factor is chronic hyperglycaemia (23).   
    The current literature suggests that DM has an impact in every stage of the natural history of TB; 
however, it has also been suggested that TB may increase the risk of developing type 2 DM (20, 24-
26). It has been shown that TB patients develop changes in carbohydrate metabolism such as 
hyperglycaemia and insulin deficiency (27). Glucose intolerance has been reported in 16.5% to 49% 





normal glucose levels when TB treatment was finished (28, 29). Other studies have presented this 
same normalization of glycaemic levels after completion of treatment in patients who had 
presented hyperglycaemia (30). Tuberculosis can temporarily impair glucose tolerance. In addition 
to that, some TB drugs including isoniazid and rifampicin have hyperglycaemic effects; and 
pyrazinamide may cause difficulties in DM control (31-35). The co-presentation DM-TB has also been 
associated with increased DM-related complications and poorer glucose control (36, 37).  According 
to WHO (2, 18), a large proportion of people with DM as well as TB are not diagnosed or are 
belatedly diagnosed, which reinforces the great dimension of the problem which remains yet 
unknown.   
    Recent systematic reviews and meta-analyses have shown that DM increases the risk of 
developing TB two to three times higher than in persons without DM, regardless of different study 
designs, background TB incidence, geographic region, and control of confounders (20, 22). The 
recognition of this important finding was consolidated by a meta-analysis of 13 observational 
studies which concluded that individuals with DM have a three-fold higher risk of developing TB (RR 
3.1; 95% CI 2.22 - 4.6) (20). A systematic review of nine studies on the subject reported that DM 
increased the risk of active TB, ranging from 1.5 to 7.8 times (38). It has been estimated that 15% of 
global active TB cases are attributable to DM (20, 39, 40). This increased risk is even greater during 
the first two years after DM diagnosis has been made and has a tendency to decrease thereafter 
(41). 
    The WHO has declared that DM is an important, re-emerging and neglected risk factor for TB (42-
44). The bidirectional association between DM and TB has been known as the next great challenge 
for global TB control (12). There is a prediction that the burden of DM will increase to close to 552 
million people by the year 2030 (45). This important interaction is more prominent in developing 
countries where TB is endemic and DM is rising. In India, it accounts for approximately 14.8% of 
incident pulmonary TB cases and 20% of smear-positive pulmonary TB cases (26). In Mumbai, TB 
was the most frequent concomitant illness in patients with DM, with 5.9% being co-morbidly 
infected in a cohort of 8,793 patients (46). The increase in the prevalence of DM has been a major 
impediment to reducing TB incident cases in the country (47). In sub-Saharan Africa, another high 
TB burden region, the number of patients with DM is predicted to double from 12 million in 2010 to 





endemic, the population attributable risk can be as high as 20% (26, 49). Data from the Texas-Mexico 
border reports that DM is the underlying attributable risk for 25% of the TB cases (50). 
    The lung is a target organ in patients with DM (51). Both acute and chronic pulmonary infections, 
such as TB, are frequently seen in patients with DM. Diabetes leads to thickness in the basal 
membrane, decreases lung elasticity and causes neuropathy, which may affect basic lung functions 
(52, 53).   However, there are scarce data in the literature concerning the relationship between DM 
and extrapulmonary TB (EPTB). Magee et al. (54) conducted a study to evaluate whether DM is 
associated with TB site and the risk of all-cause mortality in those patients being treated for EPTB.  
In the multivariate analysis, the authors found no increased odds of EPTB in patients with DM when 
compared to those without DM.  This finding aligns with those from other studies on risk factors for 
EPTB and disseminated TB (55-57), which did not find an association between DM and EPTB. Indeed,  
there is a dearth of studies concerned with this subject and the majority of existing data suggest 
that DM does not increase the risk of EPTB (54). Nonetheless, patients with poor glycaemic control 
may have substantial immune impairment and so still more likely to present extensive disease, 
similarly to what occurs with patients with both innate and acquired immunodeficiencies (7, 8). In 
this regard, as a metabolic disorder that weakens the immune system, there is need for further 
studies specially designed to examine the relationship between DM and EPTB.  
    According to the Porto Alegre TB Control Programme, the prevalence of DM among the incident 
TB cases from 2010 until 2016 ranged from 5.4% to 7.3%. Of a total of 8,827 incident TB cases, 548 
(6.2 %) patients were notified as having a previous DM diagnosis at the start of TB treatment.  
        In many parts of the globe, particularly in low to middle income countries including South 
America, DM accounts for a higher population attributable risk fraction of TB than does HIV. That is 
why global agencies such as WHO, the International Union Against Tuberculosis and Lung Diseases 
(IUATLD) and the World Diabetes Foundation have developed a collaborative framework (45) to 
provide guidance for national programmes, physicians, and other health care professionals engaged 
in all aspects of prevention and care of DM and TB on how to establish a coordinated response to 
both diseases, at both organizational and clinical levels. This initiative is a response to a growing 
concern on this important association between DM and TB and which collaborative measures should 
be put into action as a complement to and in synergy with the core activities already implemented 






   1. Establish mechanisms for collaboration through TB disease surveillance in patients with DM and 
DM surveillance in patients with TB; and conduct monitoring and evaluation of these collaborative 
TB and DM activities. 
   2. Detect and manage TB and LTBI in patients with DM. 
   3. Detect and manage DM in patients with TB. 
 
    In 2014, the World Health Assembly endorsed WHO’s new End TB Strategy which encompasses 
all fundamental aspects of the TB and DM collaborative activities. Amongst the actions already set 
in motion by the Collaborative Framework for Care and Control of TB and DM (45), there is the 
promotion of national policies discussions and research. Ending TB will require a joint plan to ensure 
that patients with DM and active TB have access to a much-needed tailored approach.   
    In short, the clear public health message is that TB and DM are both high burden diseases in their 
own rights which, once affecting concomitantly an individual, exacerbate one another resulting in 
poorer outcomes to both and thus challenging their respective global control efforts.  
 
1.4.2   DM and LTBI 
    Diabetes is a disease with an impaired host immunity, leading to increased susceptibility to 
infections. In a pilot study conducted by Restrepo (23), 79 adult contacts indicated a two-fold higher 
prevalence of DM or chronic hyperglycaemia among contacts with LTBI versus no LTBI (OR 2.39). 
The association between DM and LTBI has been very appropriately hypothesized before, but 
epidemiologic studies have been limited. The few existing studies have not shown consistent 
findings (58-64), with possible reasons being the absence of control groups (59-61) and of 
adjustment for confounders (45, 65). A recent systematic review and meta-analysis conducted by 
Lee et al. involving 38,263 individuals from one cohort study and 12 cross-sectional studies (65) 
showed that patients with DM had increased odds of LTBI (adjusted pooled OR 1.18; 95% CI 1.06 – 
1.30). One conclusion from this systematic review was that due to this small prevalence OR found, 
there was a limited incremental gain if patients with DM should be targeted for LTBI screening. In 
the case of a LTBI prevalence of 20% in individuals without DM, the expected prevalence of LTBI in 





and DM status, they reported a dose-response pattern, with the prevalence of LTBI increasing from 
25.9% in individuals without DM, to 39.1% in those with pre-DM and 43.4% in those with DM (66). 
These results would increase the incremental gain of screening DM for LTBI. 
    Potential insights into why individuals with DM might be at increased risk of LTBI might be found 
in mouse studies. Mice with DM were found to present impaired first defence mechanisms of 
clearance of the Mtb bacilli in their lungs (65). Alveolar macrophages are the first defence and it has 
been proved that both mice and human beings with DM have a defective innate immune response 
to the infection of Mtb bacilli (67-69). A contributing factor believed to be of a higher risk for LTBI is 
that patients with DM in high TB burden places frequently circulate through health care facilities 
and, thus, are in constant contact with potentially TB-infecting patients. A cross sectional study 
conducted in the United Kingdom found a 15% higher prevalence of LTBI in patients with DM 
(prevalence ratio 1.15; 95% CI 1.02-1.30), after adjusting for age, sex, ethnicity, body mass index 
and other immunocompromising conditions (70).     
    To conclude, there is some evidence suggesting that DM increases the risk of LTBI although this 
association still remains unclear. Likewise, the impact of routine LTBI screening in patients with DM 
and its cost-effectiveness are yet to be ascertained. There has been an increasing trend of 
recommendations for treating LTBI in low-burden countries, particularly in high risk groups, such as 
patients with HIV, household contacts of sputum smear-positive cases, patients on 
immunosuppressant drugs, patients with chronic renal disease on dialysis and patients with silicosis 
(71). In the WHO guidelines on the management of LTBI in low burden countries, there was no 
recommendation on the routine screening of LTBI in patients with DM. However, that was a 
conditional recommendation based on very low quality of evidence (71).   
     
1.4.3   TB-DM treatment outcomes  
    Evidence from observational studies has shown that, when concomitant, DM and TB lead to 
delays in sputum smear conversion, prolonged culture positivity at two to three months of 
treatment, higher failure rates, death, relapse (endogenous reactivation) and re-infection with a 
new strain (13, 39, 72-75). There is evidence that DM increases the risk of death during TB treatment 
(pooled RR 1.89; 95% CI 1.52 – 2.36) (75). It also increases the risk of TB relapse, with five studies 





    Two underlying factors potentially affecting outcomes become evident: poor glycaemic control 
(45) and possible suboptimal plasma levels of antimycobacterial drugs (76-78). Nevertheless, results 
have been conflicting and further research is much needed, particularly because of emergent 
multidrug-resistant TB (MDR-TB).  In a meta-analysis conducted in 2011, MDR-TB was not found to 
be significantly higher in these patients (75). About 15% of TB cases worldwide may be linked to 
DM, and the likelihood that a TB patient will die or relapse after having successfully treated is 
significantly higher if they have DM concomitantly (18). It has been suggested that the poor 
outcomes experienced by TB patients with DM may be due to the immune impairment caused by 
DM (79).  
       
1.5   Drug Induced Liver Injury 
1.5.1   Introduction to DILI  
    Drug induced liver injury (DILI) is a broad term meaning any injury to the liver by a medication, 
herb or any dietary supplement. The incidence of DILI is less than 1/10,000 persons for most drugs 
used in clinical practice (80). It is characterized by biochemical liver abnormalities, but there are 
pitfalls in the definition. Liver enzyme elevations of 1.25-2.5, 2.6-5.0, 5.1-10, or 10 times the upper 
limit of normal (ULN) value or their increase to 1.25-2.5, 2.6-3.5, 3.6-5, or 15-fold the baseline value 
usually define hepatotoxicity of grades 1, 2, 3, and 4, respectively (81). Therefore, the lack of 
homogenous definition for hepatotoxicity poses difficulties when comparing studies about a drug-
related toxicity.  
    The diagnosis of DILI is mainly based on chronological and semiological criteria (82, 83). 
Chronological criteria include the recent introduction of a potential hepatotoxic drug, biochemical 
improvement after its discontinuation and a relapse of liver abnormalities after rechallenge (81). 
The semiological factors are all the other causes which might be causing or contributing to the liver 
damage such as acute or chronic viral hepatitis or congestive heart failure, for instance.   
    Any drug or association between drugs is potentially hepatotoxic. Since numerous medications 
and diseases can cause abnormalities in liver enzymes, it is important for physicians to be able to 
distinguish the cause and take appropriate action (84). While the global incidence of DILI is small, its 
impact is significant (85). DILI is the most frequent cause for acute liver failure in most Western 





    Risk for DILI is multifactorial, as it involves inter-related risk factors. Predisposing factors have 
been identified as contributors for the emergence of DILI such as age, female sex, concomitant use 
of hepatotoxic drugs, chronic liver diseases (including chronic viral hepatitis) (88-93); and alcohol 
abuse (94) or its daily consumption (95). With some risk factors such as age and female sex, injury 
may be drug specific. For example, females have been shown to have a higher risk of DILI from 
nitrofurantoin, erythromycin, flucloxacillin and isoniazid (94, 96-100). Older age is a risk factor for 
DILI from isoniazid, whereas youth is a risk factor for DILI due to valproate and aspirin (101, 102). It 
can occur in all age groups, including children.  African ancestry has been reported to be associated 
with DILI due to phenytoin, allopurinol and trimethoprim-sulfamethoxazole (103, 104). The clinical 
spectrum ranges from asymptomatic elevation of liver tests to acute hepatitis and liver failure.  
    DILI is ultimately a diagnosis of exclusion. In most cases, there are no specific diagnostic markers 
for DILI and blood liver tests, biopsy and imaging are routinely performed in the process of excluding 
differential diagnosis (105).  Alternative causes of liver injury, such as acute viral hepatitis, should 
be sought and their absence makes the diagnosis more plausible. In many cases, the exact 
mechanism and factors contributing to liver toxicity remain poorly understood (95, 106, 107).  
    The first distinction to be made is about its predictability. Predictable DILI is generally 
characterized by a direct, dose-related injury and typically tends to have a short latency period (108), 
usually with an onset within one to five days after high doses (105). It is reproducible in animal 
models and its pathogenesis is reasonably well understood (105, 108). The most common drug 
causing predictable DILI is acetaminophen (108).  
    Most cases of DILI are unpredictable or idiosyncratic in nature, meaning that it is the 
characteristics of the host and not the drug that are responsible for the injury. The drug has little or 
no intrinsic toxicity to the liver, so not dose dependent and not reproducible in animal models. The 
pathogenesis of idiosyncratic hepatotoxicity is not fully understood yet (105). Genome studies with 
large numbers of idiosyncratic DILI cases have identified various genetic associations, such as within 
the histocompatibility complex region and linked to the histocompatibility leukocyte A antigen (HLA) 
classes I and II, suggesting an immunologic pathogenesis. In general, the HLA associations were 
drug-specific, for instance, HLA-B*5701 for flucloxacillin, but not reliable enough to warrant 
screening for alleles pre-treatment. Idiosyncratic DILI are hypersensitivity or metabolic reactions 
and have longer or variable latency. More frequently, hepatotoxicity due to TB drugs is caused by 





(109). A few other examples of idiosyncratic DILI agents are amoxicillin-clavulanate, non-steroidal 
anti-inflammatory drugs and isoniazid (108). Without adaptation, these immune and metabolic 
reactions are likely to ensue further T cell activation, cytokine release and hepatocyte injury (105). 
All forms of idiosyncratic DILI may present immunoallergic signs and symptoms, such as skin rash, 
fever and eosinophilia (110-112). The DRESS syndrome and the Stevens-Johnson syndrome are two 
such examples of a more severe drug hypersensitivity reaction with accompanying systemic 
involvement. Drugs such as macrolides, allopurinol, carbamazepine and phenytoin are among those 
that cause idiosyncratic DILI associated with immunoallergic features (103, 112-114).      
    The most frequent causes of clinically apparent DILI due to prescribed drugs, according to data 
from medical centres in the United States, between 2004 and 2013, were amoxicillin-clavulanate, 
isoniazid, nitrofurantoin, trimethoprim-sulfamethoxazole and minocycline (110). It is difficult to 
precisely estimate the real incidence of idiosyncratic DILI by specific drugs, but it is believed that, 
for isoniazid, it is one individual per 1,000 exposures; for amoxicillin-clavulanate, 1/2,500; for 
diclofenac, 1/10,000; for atorvastatin, 1/20,000; and for most drugs, 1/50,000 or more (99, 115). 
Nine out of the 10 most hepatotoxic drugs are antimicrobials, mostly antibiotics (110).           
    The second distinction to be made on DILI regards the pattern of drug injury. It may be 
hepatocellular injury, cholestasis or mixed, based on biochemical test results. An increase in serum 
alanine aminotransaminase (ALT) is more specific for hepatocellular injury than an increase in serum 
aspartate aminotransaminase (AST), which can also signify abnormalities in muscle, heart and 
kidney (95). Increases in gamma-glutamyl transpeptidase (GGT) and/or bilirubin, with little or no 
increase in AST, indicate cholestasis (95).  
    The most frequent clinical manifestation of drug-induced idiosyncratic liver injury is acute 
hepatocellular hepatitis (99, 110, 111). It may occur from five to 90 days after the start of the 
offending medication. It is also an important cause of acute liver failure, responsible for 11 to 15% 
of cases in Europe and the United States (86, 87). Isoniazid, diclofenac, nitrofurantoin, azithromycin, 
ciprofloxacin and phenytoin are widely prescribed drugs which may cause the acute hepatocellular 
injury phenotype of DILI (110, 111, 116).  
    Cholestatic DILI is caused by bile duct injury and cholestasis in the small bile canaliculi. According 
to data from Chalasani et al. (110), common causes are amoxicillin-clavulanate, azithromycin, 
ciprofloxacin, levofloxacin and azathioprine. Lastly, the mixed pattern of DILI is caused by those 





progress to liver failure. Sulfamethoxazole-trimethoprim, azithromycin, ciprofloxacin, levofloxacin 
and phenytoin are commonly prescribed drugs that may cause DILI through a mixed liver injury 
pattern (110, 113, 117).       
    Besides being either direct or idiosyncratic, there is a third type of DILI emerging, indirect 
hepatotoxicity. This type of DILI is caused by the action of the agent in the liver, rather than by its 
toxic or idiosyncratic properties. For instance, the drug may exacerbate a pre-existing liver condition 
such as non-alcoholic fatty liver disease (NAFLD) or chronic hepatitis C virus (HCV) infection, or even 
induce an immune-mediated hepatitis (105). Some chemotherapy agents can cause hepatitis B virus 
(HBV) reactivation (118) and antiretroviral agents are known to cause immune reconstitution as well 
as an exacerbation of hepatitis C (119). Another example of this type of liver injury would be the 
immune-mediated liver injury caused by immunomodulatory agents, such as monoclonal antibodies. 
The indirect category of liver injury is not a completely acknowledged category of DILI. It takes 
further the concept of DILI and contributes to its knowledge by bringing to light new possible ways 
of causing liver damage particularly in those patients with a chronic liver disease (105).          
    In the United States, the Drug Induced Liver Injury Network (DILIN) (120) reported 300 cases of 
idiosyncratic DILI cases. The mean age was 48 years, 60% were women and the largest two 
categories were antimicrobial and central nervous system agents (121). The most frequent agent in 
an acute liver failure United States registry was isoniazid, followed by sulfamethoxazole-
trimethoprim and anti-epilepsy medications (86).  
    With the intention of overcoming limitations on DILI research, country-based registries and 
international collaboration have been created in Europe and North America. In 2011, a Latin 
America DILI Network Registry (LATINDILIN) (122) was set up to prospectively identify and to study 
genetic biomarkers of genuine DILI cases. Several Latin American countries have joined this network 
and are involved in this project, such as Brazil, Argentina, Uruguay, Chile, Mexico, Paraguay, Ecuador, 
Peru, Venezuela and Colombia (122). There are common roots, but also differences in ethnicities, 
prescription patterns and drug policies and regulations. These differences pose several challenges 
but also promote development and knowledge transfer between countries.      
    In order to minimize the risk of severe liver injury, patients should be thoroughly educated about 
the symptoms of hepatitis: anorexia, nausea, vomiting, right-upper abdominal discomfort, jaundice 






1.5.2   DILI and TB treatment     
    DILI has been a long-standing concern in the treatment of active TB. The first-line TB drug regimen 
is a combination of four drugs: rifampicin, isoniazid, pyrazinamide and ethambutol (the RHZE 
regimen), the former three being associated with liver toxicity (106). In this case, the risk is believed 
to be even greater, because the three drugs are used simultaneously. There is actually little evidence 
that specific drug combinations will increase the risk for idiosyncratic DILI (105). Nonetheless, 
combinations of hepatotoxins most likely increase the risk of direct (not idiosyncratic) DILI. 
    The introduction of rifampicin in the first-line treatment of TB in Rio Grande do Sul, Brazil, 
(rifampicin, isoniazid and ethambutol, RHE) in 1977 and rifampicin, isoniazid and pyrazinamide (RHZ) 
in 1982, has led to an increase in the rates of hepatotoxicity (123). DILI in hospitalized patients due 
to regimens such as STH (streptomycin, thioacetazone and isoniazid) ranged from 0.4% to 2.2%; RHE 
from 0.8% to 7.3%; and RHZ from 2.5 to 11.1%. (123). That increase is probably explained by the use 
of two (RHE) and three (RHZ) potentially hepatotoxic TB drugs being taken concomitantly. The 
current pharmacological presentation of the RHZE tablet in combined doses currently prescribed in 
Brazil as standardized by the Ministry for Health is: rifampicin 150 mg, isoniazid 75 mg, pyrazinamide 
400 mg, and ethambutol 275mg.      
    Hepatotoxicity with the RHZ regimen has been reported with a prevalence ranging from 3 to 28% 
for idiosyncratic and intrinsic toxic reactions (124-128), and miliary TB has been a well-recognized 
risk factor for TB DILI (129).  In one study, DILI due to RHZ has been found to lead to discontinuation 
of therapy in 11% of patients (130).  In most clinical cases, drug-shared toxicity is a potential 
confounder in the interpretations of events but there is often no way to discern the contribution of 
each drug. There is a general consensus around the criteria used for diagnosing TB DILI. In the 
absence of symptoms, elevation of transaminases ≥ 5 times the ULN; and in the presence of 
symptoms, ≥ 3 times the ULN or twice the bilirubin ULN constitutes DILI (95, 131). 
    Definitive conclusions regarding DILI during TB treatment are difficult to achieve because studies 
vary as to study designs and methodologies, populations, use of multiple drug regimens, definitions 
of DILI and different blood tests monitoring practices. All in all, the risk of DILI reported in various 
studies ranges from 0.6% to as high as 33% (95). However, the international literature reports a 
small and acceptable risk of DILI caused by a combination of isoniazid, rifampicin and pyrazinamide 
(132-135). Data reported on the proportion of severe hepatotoxicity due to RHZ from the United 





    A meta-analysis of studies involving the use of a multiplicity of TB drug regimens predominantly 
in adults has shown an incidence rate of liver toxicity of 1.6% with isoniazid alone; 1.1% with 
rifampicin alone; and 2.6% with isoniazid and rifampicin co-administration (139). Subsequent 
studies with patients treated with isoniazid alone have reported that transaminases elevations of 
three times the ULN in symptomatic individuals and five times the ULN in asymptomatic individuals 
occurred in 0.3% of cases (140). Nevertheless, in larger reviews, the range has been as low as 0.1% 
to 0.56% (140-142).   
    The risk of developing isoniazid related hepatitis is age related and approximate case rates by age 
are: 0 per 1,000 for persons under 20 years of age; 3 per 1,000 for persons in the 20 - 34-year age 
group; 12 per 1,000 for persons in the 35 - 49-year age group; and 23 per 1,000 for persons in the 
50 - 64-year age group (141). Patients from 36 to 50 years have a 1.2% risk of isoniazid-induced 
hepatitis (143), but more recent studies have found much lower overall rates of isoniazid 
hepatotoxicity: 0.1% to 0.3%  (141, 144).  
    It is important to note that studies differ in terms of their definitions of hepatitis and many authors 
use the terms hepatotoxicity and hepatitis interchangeably. Drug-induced hepatocellular jaundice 
is a serious lesion, with mortality from 10% to 50% (145). The reason for that is that considering the 
liver’s great capacity for bilirubin excretion, it must be extensively damaged before jaundice is 
perceptible. So much liver damage is too extensive to recover from. In 1999, Robert Temple 
articulated a modified version of this observation for use in controlled clinical trials and as a 
screening threshold. He called it Hy’s Law, after the late Dr Hyman Zimmermann, who repeatedly 
made the clinical observation that drug-induced hepatocellular jaundice is a very serious lesion. 
Patients with all of the following criteria are defined as Hy’s Law cases:   
 
   1. ALT or AST >3 times the ULN;  
   2. Total bilirubin >2 times the ULN;  
   3. It should not be primarily cholestatic;  
   4. It should not be caused by any disease, but by a drug (145).  
 
    Clinical hepatitis is seen in 1-6% of patients on isoniazid only (139). The mortality range lies 
between 0.0 - 0.3 per 1,000 persons (median 0.04) (146), but the precise data to provide a fatality 





Surveillance Study of 13,838 persons taking isoniazid, there were 8 deaths among 174 cases of 
hepatitis (107). Usually enzyme levels return to normal, despite continuation of the drug, but in 
some cases progressive liver dysfunction occurs. If any symptoms of hepatitis appear, or if signs 
suggestive of hepatic damage are detected, the drug should be promptly discontinued. 
    Interactions between genetic, host and environmental factors contributes to drug induced 
hepatotoxicity due to TB drugs. Risk factors for isoniazid toxicity include chronic viral hepatitis B and 
C (a 5-fold increase) (92, 147), HIV infection (3 to 5- fold) (92, 147), alcohol abuse, old age, female 
sex (OR 10.59 and RR 4.0) (109, 148-155), and concurrent use of rifampicin or pyrazinamide (107) 
or other hepatotoxic drugs. One study has shown that co-infection with both HCV and HIV has 
elevated the risk of DILI due to TB drugs more than 14-fold (92). Other clinical factors that increase 
the risk of drug-induced hepatotoxicity during TB treatment include extensive TB disease and 
malnutrition (92, 95, 107, 156). Abnormal baseline transaminases are an independent risk factor for 
DILI (95) so that the severity of DILI seems to be greater when an underlying liver disease is present, 
suggesting a summation of injuries (157).    
    In an analysis undertaken in Canada (137) the incidence of all major adverse events was 1.48 per 
100 person-months of exposure for pyrazinamide as compared with 0.49 for isoniazid, and 0.43 for 
rifampicin. The incidence of pyrazinamide-induced hepatotoxicity during treatment for active TB 
was thus substantially higher than those attributable to the other first-line TB drugs and higher than 
previously recognized. Pyrazinamide seems to be the most hepatotoxic drug of the first-line regimen 
(137, 158-160).  On the other hand, rifampicin alone is possibly associated with a lower potential 
for hepatotoxicity than isoniazid and pyrazinamide (34, 106, 159, 161). So much so, that the 
American Thoracic Society (ATS), the Centre for Disease Control (CDC) and the Prevention/Infectious 
Disease Society of America currently recommend that rifampicin be the first drug to be re-started 
after recovery from an episode of TB therapy-induced hepatitis (159).  
    One prospective cohort study from Spain has shown the incidence of TB drug-induced DILI 
(reflected by serum transaminases more than three times the ULN) to be higher in the group with 
risk factors (18.2 %) than in the group without them (5.8 %; OR 3.5). Severe DILI (considered as to 
be serum transaminases above ten times the ULN) occurred in 6.9 % of the risk factor group and in 






1.5.3   Adaptation   
    DILI encompasses a variety of clinical entities, and their discussion is beyond the scope of this 
study, but one of them has important clinical relevance to TB management and that is hepatic 
adaptation. Exposure to certain drugs may result in physiologic adaptive responses. Once injury 
starts, an upregulation of hepatoprotective mechanisms respond, such as hepatocyte proliferation 
and drug-metabolizing enzyme activities, attenuating toxin-related injuries (105). It may also be 
through down-regulating hypersensitivity reactions to drugs and its metabolites (105). Rarely does 
this kind of drug-induced injury lead to inflammation, cell death or histopathologic alterations. This 
is reflected in mild and transient elevations of transaminases. However, certain toxins such as alcohol 
interfere with the effectiveness of these adaptive and protective responses. Up to 20% of individuals 
on isoniazid preventive therapy have experienced slight, asymptomatic and transient transaminases 
elevation (95, 150, 162-165). In the cases when adaptation does not occur, enzyme elevations and 
cholestasis continue to rise and symptoms appear.       
 
1.5.4   Advice on monitoring 
    In order to assist physicians to decide whether elevated transaminases reflect adaptation or initial 
liver injury, DILIN and other groups currently recommend that TB drugs should be discontinued if 
ALT and AST are ≥ 5 times the ULN in the absence of hyperbilirubinemia or symptoms; or ≥ 3 times 
the ULN in the presence of symptoms or hyperbilirubinemia (bilirubin ≥ 2 times the ULN) (120). 
Various guidelines for the management of DILI have been issued by the ATS (95), British Thoracic 
Society (BTS) (166), WHO (167) and IUATLD (168). Several national and international TB control 
guidelines (95, 166-172) address the issue of DILI; however, not all of them establish 
recommendations on routine monitoring of liver tests and detailed advice on management. Some 
of those that give more detailed advice on monitoring and management strategies are the 
guidelines from DILIN (120), the Department of Health and Community Services of the Northern 
Territory of Australia (171), the ATS official statement on hepatotoxicity of antituberculosis therapy 
(95), the BTS guidelines on chemotherapy and management of TB (166, 173) and the Brazilian 
National TB Control Programme (PNCT) (172). The ATS document (95) is the most comprehensive 
and stipulates that all patients should have baseline liver tests with subsequent monitoring being 
subject to the presence of risk factors. It suggests monitoring at a variable time between two and 





subsequent monitoring in patients with previous chronic liver disease, with weekly tests for the first 
two weeks and then at two weekly intervals for the first two months. Regular biochemical 
monitoring is not advised for those without chronic liver disease and normal baseline liver tests, 
which should be ordered only for those presenting symptoms of liver disease. According to the 
Australian guidelines (171), monthly tests are not routinely required unless certain circumstances 
are present, such as abnormal baseline transaminases, underlying chronic liver disease, HIV 
infection and significant alcohol consumption. The Brazilian PNCT (172) recommends that 
biochemical monitoring be performed monthly in case of symptomatic patients or in those 
presenting risk factors for DILI. In Hong Kong, TB specialists deem a stepwise increase in 
transaminases levels and a persistent rise in bilirubin levels to be more significant as an indicative 
of DILI than those more frequently used threshold values (106).         
    The main risk factors for TB DILI are well known and have been extensively discussed in the 
literature; less well-established, however, are the different weights with which they contribute to 
increase the risk of DILI. There has not been found any studies specifically on risk stratification of 
patients before the start of treatment based on biochemical tests.  
    There seems to be a consensus across national guidelines about the discontinuation of therapy 
when the transaminases levels reach the already mentioned thresholds of ≥ 3 times the ULN in the 
presence of symptoms and ≥ 5 times the ULN without them.  
  
1.6   Diabetes, the liver and comorbidities 
    The collision of the growing DM problem and its concomitance with TB and, additionally, the 
existing TB-DILI problem, has potential to become a significant public health problem if DM 
enhances the risk of TB DILI.  One important clinical implication of the association between DM and 
chronic liver disease is the impact it has on drug management. This section presents background 
information on the possible associations between DM and NAFLD, chronic viral hepatitis, alcohol 
consumption and HIV infection.     
    Globally, type 2 DM accounts for most of DM cases (18) and is associated with metabolic 
syndrome (obesity, insulin resistance and dyslipidaemia). It has been observed that fatty liver, 
obesity and insulin resistance act as co-factors for liver injury (174-176). Diabetes itself has been 





disease (177). Patients with type 2 DM usually are older and frequently have comorbidities with the 
need for additional medication, or have harmful drinking patterns, which are associated with DILI. 
    Other conditions also associated with DM include alcohol intake, chronic HCV infection and 
hemochromatosis (174, 175, 178-180). Also, polypharmacy is very common in the elderly DM 
population. Relevant to the present study is the frequent use of DILI-causing drugs, such as statins, 
by these patients. Few studies have assessed the long-term safety of antidiabetic drugs in patients 
with chronic liver disease and this could be extrapolated to other potentially hepatotoxic drugs (181). 
In addition, one chronic complication of DM that may contribute to an increased risk of liver toxicity 
is chronic renal disease, which is also a potent risk factor for TB.    
 
1.6.1   Non-alcoholic fatty liver disease 
    Normally, the liver is devoid of fat and fatty changes often coexist with necro-inflammatory and 
fibrotic changes in the setting of both metabolic and viral injuries such as chronic HCV and HIV 
infection (182). NAFLD is considered a hepatic manifestation of metabolic syndrome (183). The 
definition of NAFLD requires that there is evidence of steatosis either by imaging or histology; and 
absence of any alternative causes for secondary liver fat deposition such as substantial alcohol 
consumption, steatogenic drugs, or hereditary disorders (184). It is a chronic condition increasing in 
prevalence with the rise of obesity and type 2 DM rates (48). Data from various studies indicate that 
the prevalence of NAFLD in the general population ranges from 6.3% to 33% (183). In Europe and in 
the United States, its prevalence based on imaging studies, ranges from 25% to 30% in the adult 
population (185). The highest prevalence of NAFLD is seen in South America and in the Middle East, 
while Africa presents the lowest prevalence (185). There seems to be an “inverted” U-shaped 
distribution of its prevalence across ages. Younger and older individuals are relatively spared from 
presenting NAFLD (186). Also, men are at a higher risk of presenting NAFLD, when compared to 
women (187, 188). In a study with nearly 400 individuals, the NAFLD prevalence defined by 
ultrasound was 46%, and the histologically confirmed prevalence was 12.2% (189). Clinical disease 
ranges from mild elevation of liver enzymes to severe disease with fibrosis (183). NAFLD has not 
been proven to be a risk factor for DILI in general (108).          
    Convincing evidence shows an association between NAFLD and type 2 DM (190, 191). NAFLD is a 





up period of 5 years (192, 193). In an ultrasonography study, 69% of patients with type 2 DM 
presented NAFLD (194).  Its prevalence in patients with DM ranges from 30% to 75% varying 
according to age, ethnicity and diagnostic methods applied (195). Besides, it has been noted that 
fatty liver may be a shared condition playing a key role in the development of type 2 DM in patients 
with chronic HCV or HIV infections (182).   
     
1.6.2   DM and alcohol consumption 
    Alcohol consumption can have an impact not only on the incidence of a range of diseases, but 
also on their courses and outcomes. The incidence rate of DM is significantly greater among those 
with alcohol drinking disorders compared to matched controls (196).  Patients with alcoholic liver 
disease have a high relative risk of developing DM, and this risk is directly related to the amount of 
ingested alcohol (197). There is epidemiological evidence from a number of recent prospective 
studies indicating a close relationship between alcohol consumption and the risk of development of 
type 2 DM (198-201).  
    While heavy alcohol consumption is a risk factor for DM, regular light-to-moderate quantities of 
alcohol may decrease this risk (202, 203). Moreover, chronic alcohol intake has been associated with 
poor glycaemic control in individuals with DM and has a negative effect on DM outcomes (202, 203).  
    Diabetes frequently co-occurs with alcohol abuse or dependence (204). The development of both 
insulin resistance and impaired glucose tolerance, conditions that precede the onset of type 2 DM, 
are closely linked to alcohol dependence (205). A study by Engler et al. (206) documented that 13.4% 
of DM patients in an outpatient clinic were at-risk drinkers, of which 11.1% met criteria for alcohol 
dependence. At-risk drinkers are those considered likely to experience negative health 
consequences as a result of this drinking behaviour and are at an increased risk for future alcohol-
related adverse health events. In 2011, Cullman et al. (198) conducted a prospective study to 
investigate the influence of alcohol consumption and specific alcoholic beverages on the risk of 
developing pre-DM and type 2 DM in a Swedish population after a follow-up of 8-10 years. A high 
alcohol intake was found to increase the risk of pre-DM and type 2 DM in men, including binge 
drinking. In women, the associations with glucose metabolism were more complex. There was a 
decreased risk with low or moderate alcohol intake and an increased risk with high alcohol intake, 





drinking and pre-DM and type 2 DM in women. This is in contrast with a Finnish cohort study (209), 
that found no association between binge drinking and type 2 DM in men, but a doubled risk in 
women.   
     
1.6.3   DM and Hepatitis B infection 
    Globally, HBV infects 350 million people (210). The WHO informs that the areas of high prevalence 
of HBV infection are similar to the global TB epidemiological high burden regions, such as sub-
Saharan Africa and South Asia, where the prevalence is estimated to be between 8% and 20% (128). 
A Brazilian study conducted in Rio de Janeiro has reported a prevalence of 3.2% of hepatitis B surface 
antigen (HBsAg) positive patients with active TB (211). Another one, conducted in Goiânia, in 2011, 
has found a prevalence of 2.8% (212) in TB patients with or without HIV. In 2011, the incidence rate 
of confirmed cases of HBV (either by HBsAg, anti HBc IGM or HBeAg) in Goiânia was 9.3 per 100,000 
population (213) .  
    HBV is known to lead to liver cirrhosis and hepatocellular carcinoma (210), but its association to 
DM has been controversial and studied less extensively than the HCV association to DM. A few 
longitudinal (214) and cross-sectional studies (214) have found no significant association between a 
positive serology for HBsAg and DM. However, some studies showed an increased prevalence of DM 
in HBsAg positive patients when compared to HBsAg negative patients (215-217). Papatheodoridis 
et al. studied 434 patients with histologically documented hepatitis B or C and found that DM was 
present in 13% (58/434) (215).  There was no difference between chronic HBV (14%) and HCV (13%). 
Lao et al. found an independent association between HBsAg carrier status with gestational DM (RR 
3.51; 95% CI 1.83 – 6.73) (216). Lastly, Li-Ng et al. (217) investigated the association between HBV 
infection and DM among Asian Americans and Pacific Islanders. Overall, DM prevalence was higher 
in patients with HBV than in those without HBV (58.9% vs. 33.3%, P < 0.001), and this remained so 
after adjustment for confounders (OR 3.17; 95% CI 1.58 - 6.35). 
    A cohort study conducted by Hong et al. in 2017, with a large sample of individuals with a low risk 
of DM and adjustment for multiple covariates, found a clear association between HBsAg and both 
DM incidence (HR 1.23; 95% CI 1.08-1.41; P = 0.007) and prevalence (OR 1.17; 95% CI 1.06 - 1.31; 
P = 0.003) (214). This study adds evidence on a prospective association of HBV infection and DM 





growing body of research suggesting that DM is a metabolic complication of HBV, but evidence is 
still inconsistent. There is need for further longitudinal studies with longer periods of follow up to 
better characterize the effect of HBV on the risk of DM.  
     
1.6.4   DM and Hepatitis C infection 
    The association between HCV and type 2 DM has been known for over 20 years (218). DM and 
HCV infection are prevalent diseases worldwide and epidemiological studies have shown that they 
are associated (219-221), regardless of differences in ethnicities and geographical regions (222). It 
is estimated that 24% to 64% of chronic HCV patients have type 2 DM (223, 224), and it has been 
shown that HCV infection can precede type 2 DM diagnosis in as many as 73% of cases (223, 225, 
226), although that could be related to age of acquisition rather than cause and effect. A large 
number of studies have revealed an increased risk for type 2 DM in patients with chronic HCV 
infection (227-230) and the overall prevalence of DM among chronic HCV patients in North America, 
Europe, Middle East and Asia ranges from 13% to 33% (231-233). These are demonstrably higher 
than age-matched prevalence in the general population, from which these samples are drawn. 
Indeed, HCV has been described as an independent predictor for DM (234).     
    Hepatitis C virus infection is a significant global health burden. According to WHO, it is estimated 
that HCV infects 170 million people globally, around 3% of the world population (1, 4). The outcome 
of chronic HCV is variable and over a period of approximately 25 to 30 years, around 20% to 30% of 
patients develop cirrhosis, which increases the risk of hepatocellular carcinoma (1% - 4% per year) 
and liver-related death. Besides causing cirrhosis and hepatocellular carcinoma, HCV is thought to 
be the cause of a number of metabolic disorders (235). In addition, there is evidence that insulin 
resistance and type 2 DM are strongly related to worse outcomes in HCV patients and are 
independent predictors of liver-related mortality. They are associated with increased fibrosis 
progression, cirrhosis decompensation and an increased risk of hepatocellular carcinoma in a variety 
of studies (236-241). In fact, insulin resistance has been demonstrated to be an independent 
predictor of fibrosis in chronic HCV individuals (242, 243). A review conducted by Desbois and 
Cacoub (235) searched for a relation between liver fibrosis and DM, insulin resistance and impaired 
fasting plasma glucose. Twenty-six out of 30 studies reported a significant association between 
glucose abnormalities and liver fibrosis severity (OR ranging from 1.28 to 13.72) (235). The 





    The clinical interactions between HCV and insulin resistance are multi-layered and result in the 
progression of HCV infection. The prevalence of insulin resistance or type 2 DM in patients infected 
with HCV has been shown to be high. A study conducted at an outpatient clinic found a 30% 
prevalence of glucose abnormalities in HCV patients (180). A systematic review of 35 observational 
studies found a pooled OR 1.7 for type 2 DM in HCV positive patients compared to HCV negative 
controls and a pooled OR 1.9 when comparing to HBV infected controls (245). A community-based 
prospective study showed an increased risk of developing DM in HCV positive patients when 
compared to HCV negative patients (HR 1.53; 95% CI 1.29 – 1.81), after adjustment for age and body 
mass index (246).  
    A review conducted by Desbois and Cacoub, in 2017, reported that 16 out of 20 studies found a 
significant association between glucose abnormalities (insulin resistance and DM) and HCV infection 
(235). Seven studies with multivariate or adjusted analyses showed an OR between 1.2 and 3.77 
(235). When compared to HBV-infected patients, seven out of 11 studies found a significant 
association between DM and HCV (235). 
    Diabetes has been clearly shown to increase the risk of hepatocellular carcinoma among patients 
with HCV. Several studies have found a substantial association between DM and insulin resistance 
and the development of hepatocellular carcinoma in the follow-up of HCV infected patients, with 
HR ranging from 1.10 to 6.9 (247-250).   
    Although there is a substantial body of evidence in favour of a link between DM and HCV infection, 
some studies have found diverging results (215, 251, 252). Therefore, there is still need for further 
research to better understands the metabolic pathways connecting insulin resistance, metabolic 
syndrome, DM and HCV. Regardless, a vast majority of studies have shown a two to tenfold increase 
of type 2 DM in chronic HCV-infected patients, compared to other liver diseases (228, 253-255) and 
DM has been recognized as part of the spectrum of HCV-associated diseases by a large body of 
research (256, 257).  
    To conclude, HCV infection and DM are both highly prevalent chronic diseases of epidemic 
proportions and a large body of evidence has attested to this two-way association: HCV infection 
leads to DM, and DM worsens HCV outcomes (222).  





1.6.5   DM and HIV infection 
    Recent studies have suggested that, currently, the life expectancy of HIV-infected patients may 
approach that of the general population (258). Consequently, the increasing number of older HIV 
positive patients results in an increased burden of age-related comorbidities to be managed both by 
physicians and policy makers. Patients with HIV have been found to be at a higher risk of incident 
cases of type 2 DM compared to the general adult population (259), although the mechanisms 
involved are yet to be better understood. The use of some antiretroviral drugs, the co-infection with 
HCV and the HIV-induced systemic chronic inflammation are amongst the conditions involved (260-
263). Therefore, further research is needed to further elucidate possible contributing factors for the 






CHAPTER 2  -  JUSTIFICATION, AIMS, OBJECTIVES AND HYPOTHESES 
 
2.1   Justification 
    National TB control programmes have a responsibility for devising, implementing, monitoring and 
evaluating public policies to reduce the health and social burden of TB, and then further disseminate 
scientific information and provide guidance. In 2012, the United Nations Conference on SDG held in 
Brazil established the SDG for the global health agenda as a substitution for the eight Millennium 
Development Goals, which ended in 2015 (264). The third target of the third SDG’s health goal 
(ensure healthy lives and promote well-being for all at all ages), is focused on ending the TB, AIDS 
and malaria epidemics, among others, by 2030. The fourth target is about reducing by one third, 
through prevention and treatment, the premature mortality from non-communicable diseases 
(264).       
    Approximately 439 million people worldwide are estimated to develop DM by the year 2030 (265). 
Type 2 DM, which accounts for approximately 90% of DM cases, has become a global public health 
concern. In many countries, the current epidemic proportions of DM are increasingly becoming a 
key determinant of TB. Diabetes prevalence has been rising more rapidly in middle and low-income 
countries, which are the ones where the burden of TB is greatest (18). Of all the countries with this 
increasing trend of DM cases, it has been reported that 70% occur in developing countries and 47% 
in developed ones (266). Several aspects of this subject still need robust evidence to inform global 
health policies both on TB and DM programmes. Indeed, DM is now prominent on the global health 
agenda and is recognized as a challenge to national TB control efforts. Consequently, TB control 
programmes should target patients with DM for any intervention that may have an impact on TB 
outcomes.  
    In 2014, WHO’s new End TB Strategy established the following global milestones for 2025, relative 
to 2015 data: a 50% reduction in TB incidence and a 75% reduction in TB mortality; and for 2035, a 
90% reduction in TB incidence (<10 cases/100.000 population globally) and a 95% reduction in TB 
mortality (267). Within the scope of the End TB Strategy and the new SDG, actions focused on a 
better control of DM will have a positive impact on the global burden of TB.  
    One important question to TB control programmes worldwide is about the impact that DILI caused 





worse TB treatment outcomes. If, in addition to that, they present an increased risk of DILI due to 
particularities related to DM, then it would be of paramount importance to identify risk co-factors 
in this population early on. DILI poses an additional threat to a treatment which is already long by 
nature and frequently fraught with difficulties. The End TB Strategy states that comorbidities should 
be identified and managed accordingly, and this could be extrapolated to identifying and managing 
whatever conditions might hinder a successful TB treatment in the DM population. If TB policy 
makers and implementers succeed in mitigating the serious consequences of DILI, then these 
patients will stand a better chance of completing a successful treatment. DM is common amongst 
TB patients and, as well as being a direct cause of hepatic dysfunction (for instance, through fatty 
liver), DM is associated with a number of comorbidities that can cause hepatic damage. Thus, it is 
important for TB programmes to understand whether DM is an important independent risk factor 
for DILI or an important co-factor for DILI due to other hepatotoxic comorbidities; or indeed not 
actually a condition for which heightened vigilance for DILI is necessary. Those are the questions 
that this study sets out to address. There is a dearth of evidence on this issue presently available to 
inform policy makers on this particular matter.  
 
2.2   Aims and objectives  
    The aim of this study is to determine whether DILI is more frequent amongst TB patients with DM 
than without it; and to identify co-factors predictive of an increased risk of DM-associated DILI. The 
objectives are twofold: 
    1. To undertake a case-control study of TB patients with and without DILI to determine the effect 
of DM as a risk factor for DILI; 
    2. To further investigate predictors of DILI in patients with DM and any co-factors associated with 






2.3   Hypotheses 
    1. DM patients taking the RHZE regimen for active TB will be more likely to develop DILI than those 
without DM.  
    2. Any increased risk for DILI in those with DM will be associated with important co-factors that 






CHAPTER 3  -  METHODS 
 
3.1   Study design 
    This is a case-control study. The case-control design was chosen over a cohort study. The large 
number of TB patients who were followed up during the 4.5-year period of the study precluded the 
decision to conduct a cohort study. A retrospective cohort would have entailed data extraction from 
a much larger number of sets of case notes, which would have been unfeasible. A prospective cohort 
study would take too long to follow up and recruit participants (the DILI outcome is sufficiently 
uncommon that it would take several years to recruit a few hundred cases). Amongst the 
advantages of a case-control study design, it should be mentioned that it is suited for studying rare 
conditions; is relatively quicker to conduct than a prospective design, as the outcome and the 
exposures of interest have already occurred in the past; it is less expensive; and it allows for studying 
associations without the need for lengthy follow-up periods.  As to its disadvantages, selection bias 
among controls and information bias were considered as possible issues, as these are the main types 
of bias that case-control studies are susceptible to. The temporal sequence between the exposures 
and the outcome was not an issue in this study and this is because the outcome, DILI, always post-
dated the main exposure, DM.  
 
3.2 Matching 
    Matching is a method for reducing the effects of confounding variables.  Both the controls and 
the cases are selected with no differences with respect to certain characteristics. It can be done 
either by individually pairing a case to one or more controls or by frequency matching, which means 
that the groups of cases and controls will have the same overall distribution of the matching 
variable. Frequency matching does not control confounding to a great degree, and further statistical 
methods are needed; however, it does improve comparability between cases and controls, 
illustrated, for example, by the way age-matching would avert comparison of cases of neonatal 
jaundice with an inappropriate control group of people without jaundice, of all ages.  
    There are methodological issues raised by matching in case-control studies. For instance, by 
completely precluding detection of any association between the exposure that cases and controls 





to over-matching, and once overmatching occurs, it cannot be corrected later in the analysis. Other 
disadvantages would include adding complexity (in terms of time spent and costs) to the 
recruitment phase; and the exclusion of cases, if matching controls cannot be found. Those issues 
are beyond the scope of this thesis, but the decision to conduct an unmatched case-control study 
was based mostly on the reasoning that once patients have been matched in the recruitment phase 
of the study, there is little flexibility in the analysis phase. The effect of the matching variable on the 
outcome variable can no longer be studied. It was deemed to be more meaningful to the study if all 
the pertinent exposures were included in the statistical analysis phase and the confounding 
variables controlled during the analysis by use of adequate statistical methods.  
   
3.3   Description of the study sites and setting 
3.3.1   TB Clinic referral network 
     The TB referral clinics are TB clinics in the secondary level of health care in the Brazilian public 
health service. Apart from their attending to patients, these TB clinics also provide training for 
medical residents and assistance to general practitioners on any TB-related issues, whenever 
necessary. At the outset of this study, there were five such clinics in Porto Alegre, all of which were 
data sources for the present study. A small number of TB patients is treated in primary care, by 
general practitioners or family physicians, but only uncomplicated pulmonary TB (PTB) cases which 
are eligible for treatment with the first-line drugs, RHZE, and in the absence of adverse effects. DILI 
is not a condition managed in the primary care setting. According to the PNCT guidelines and 
recommendations in Brazil, patients should be referred from their general practitioners to a TB 
referral clinic if they meet the following criteria: 
    
   1. The TB diagnosis process is facing difficulties;  
   2. Major adverse effects, such as allergy, DILI, neurotoxicity, nephrotoxicity; 
   3. Serious comorbidities such as transplanted patients, immunosuppression, chronic liver 
diseases and chronic renal disease; 





    The municipal TB Control Programme of Porto Alegre had the following additional criteria 
included: TB in children under 12 years of age, pregnancy and EPTB. All cases of PTB in adults without 
the comorbidities mentioned above and eligible for the first-line regimen, are treated by some 
family doctors and general clinicians. A new public policy on the decentralization of TB treatment 
has been implemented for the last four years, approximately. It has been a process fraught with 
difficulties and one which has evolved heterogeneously across the city. It was not possible to gather 
accurate data on the proportion of patients followed up in the primary care clinics vs. TB clinics, but 
patients are still largely managed in the latter. All suspected DILI cases are routinely transferred to 
the TB clinics and then managed by the TB physicians, even those cases who are successfully re-
challenged and do not need a change of treatment. Primary care clinics are not allowed to decide 
on any change of TB treatment.    
    Once a patient is started on TB treatment, there are standard procedures conducted, preferably 
in the first appointment at the TB clinic. In order to promptly diagnose infectious comorbidities, 
rapid tests for HIV (HIV Test Bioeasy, by Standards Diagnostic Inc, Republic of Korea); HBsAg (VIKIA 
HBsAg by bioMérieux SA, France); HCV (ALERE HCV, by Standard Diagnostic Inc, Republic of Korea) 
and syphilis (ALERE Syphilis, by Standard Diagnostic Inc, Republic of Korea) are performed by the TB 
nurses. Not all patients are tested by rapid tests, as these may be ordered together with a more 
comprehensive biochemistry panel, according to the physician’s discretion. Another possible 
scenario is that the patient has been previously tested, either at the hospital or by their attending 
physician. In such case, the TB physician may not be aware of those tests results. Consequently, a 
certain heterogeneous pattern of biochemical analyses across all the TB clinics was anticipated, and 
that might happen either at the outset or during follow-up at the TB clinic. Tests for DM screening 
during TB treatment are subject to the physician’s discretion.               
    Although there are national guidelines on the monitoring of DILI, those routines were also 
expected to be heterogeneous. Some patients are monitored regularly in the absence of risk factors 
or symptoms, while others are tested only if risk factors are present or symptoms occur.   
    The incident TB case is notified on the first medical appointment, through a hand-written 
Information System of Notifiable Diseases (SINAN) Form. It is then captured by the TB 
Epidemiological Surveillance Team (General Coordination of Health Surveillance (CGVS)), where it is 
recorded on a database, while a paper copy of the form is kept together with the patient records at 





    If a patient should present alterations on liver function tests, the physician orders a viral hepatitis 
panel comprised of anti-HAV IgG/IgM, total anti-HBc/anti-HBc IgM, HBsAg and anti-HCV. Once the 
physician diagnoses a case of DILI and decides that a change of drug regimen is needed, the patient 
is then registered on a nationwide electronic system of notification of cases needing special 
treatments, the Information System of Special Tuberculosis Treatments, SITETB.  
 
3.3.2   Tuberculosis Notification Database 
    The TB control programme requires that all incident TB cases are notified when the patient is put 
into treatment, during their first medical consultation. The notifications are done by filling out a TB 
Notification Form, SINAN, which is subsequently sent to the TB Epidemiological Surveillance Team 
at the Health Surveillance Department and kept at the electronic Tuberculosis SINAN Database. 
Appendix A shows the tables with the number of notified incident cases in all the five referral TB 
clinics in Porto Alegre per year, from 2013 to 2017.  Between 453 and 802 patients were notified as 
incident TB cases between 2013 and 2017 (Appendix A, Table A1), with a median of 635 patients 
and interquartile range (IQR) 529 – 667. Notification numbers from the referral clinics decreased 
throughout the years due to the decentralization project that had been under implementation. 
Treatment outcomes during the same period were as follows (Appendix A, Tables A2 - A6): cure was 
achieved in a median of 384 patients (IQR 317 – 406); default from treatment occurred in a median 
of 129 patients (IQR 84 – 158); death occurred in a median of 20 patients (IQR 19 – 21); and discharge 
by transfer, in a median of 20 patients (IQR 17 – 21). 
 
3.4   Study population 
    The study population were patients of all ages who were treated for TB with the first-line regimen 
who either did or did not develop DILI during their treatment. The results from the study are 







3.4.1   Cases definition, selection criteria and collection 
3.4.1.1   Cases definition 
    Cases were TB patients who presented with DILI during treatment with RHZE, either in fixed dose 
combination or in individualized tablets. DILI is defined as drug induced liver injury, as diagnosed by 
the attending physician with a resulting change in the TB treatment prescribed.  For the purposes 
of this study, DILI was not defined by a threshold increase in transaminases or bilirubin but rather 
by this operational definition. The DILI episode must have been severe enough for the physician to 
decide in favour of a change of treatment, including patients who went through an unsuccessful re-
challenge.   
    Patients who presented DILI and were successfully rechallenged with RHZE did not need a change 
of treatment and, therefore, were neither reported onto SITETB, nor in any registry, so could not be 
captured. The rationale for the definition of DILI cases as “cases who needed a change of treatment” 
was that they reflect the most severe DILI cases, which were the focus of the investigation. That was 
the best quality data. 
 
3.4.1.2   Selection of cases 
3.4.1.2.1   Inclusion criteria 
    Patients were selected as cases if they presented the following criteria: 
    1. Presentation of DILI diagnosis from 01 January 2013 to 31 July 2017.  
    2. Patient originated from a general practitioner’s clinic, TB clinic or discharged from a hospital. 
    3. Registration on the Information System for Special Tuberculosis Treatments electronic platform 
from 01 January 2013 until 31 August 2017 – in so far as the DILI episode happened no later than 31 
July 2017 - due to a need of change of treatment prescribed. 
    4.  Follow-up in one of the five TB clinics in Porto Alegre, Rio Grande do Sul, Brazil, either before 






3.4.1.2.2   Exclusion criteria  
    Patients were excluded based on the following criteria: 
    1.  Patients who were given rifabutin instead of rifampicin, as the former is not considered as 
potentially hepatotoxic as the latter.  
    2. Patients missing any one of the three hepatotoxic drugs, namely rifampicin, isoniazid or 
pyrazinamide. TB DILI is caused by the synergistic hepatotoxic effect of the three drugs taken 
concomitantly and patient groups (cases and controls) must only be compared if they are taking the 
same drug combination. 
    Patients were not excluded if they were not treated with ethambutol, as this drug is not 
associated with hepatotoxicity. Similarly, patients who died were not excluded.  
 
3.4.1.3   Cases collection 
    The cases were obtained by reviewing all the patients registered on the Information System of 
Special Tuberculosis Treatments, the SITETB database, requiring a change of treatment due to 
hepatotoxicity whilst being treated with RHZE. Besides those patients who had DILI, there were also 
those presenting with a previous chronic liver condition, to whom RHZE would be best avoided. As 
a result, they were given a different drug regimen from the start. They were not DILI cases. Although 
that represented a different category in the SITETB, those two groups were classified together under 
the term “hepatotoxicity”, so needed be reviewed as well. Conversely, as a way of capturing any 
hepatotoxicity case that might have been misclassified as “allergy” as the reason for being on 
SITETB, all the patients registered as having had any allergic reaction were considered as potential 
DILI cases and reviewed. Patients registered as “intolerance to drugs” were also reviewed, for the 
sake of thoroughness.  
 
3.4.1.3.1   SITETB Database 
       SITETB is an electronic information system for notification, management and closure of TB and 
non-tuberculous mycobacteria (NTM) infection cases. It was implemented in 2013 and first created 





developed into managing cases of mono- and poly-resistance as well as major adverse reactions. 
The reasons for a special treatment, that is, any drug regimen different from the RHZE tablet in fixed 
dose combination, may be numerous: mono-resistance, poly-resistance, multidrug- resistance, NTM 
infection, significant side effects, incompatibility with concomitant drugs, chronic liver disease; and 
a need for reduced dosages, such as in patients with low body weight, chronic renal disease or a 
rechallenge with RHZE. Once onto SITETB, the case will be subject to an assessment by a validator 
from another Brazilian state who, in case of agreement, will grant authorization for the delivery of 
the new drugs to the TB clinic. All cases are monitored electronically monthly until their final 
outcome and closure. It provides data on demographics, TB diagnosis, comorbidities, previous TB 
episodes and outcomes, and pharmacological surveillance. It is a valuable monitoring tool that 
provides useful and real-time data nationwide for both clinical and research purposes, as well as 
feedback to the PNCT. 
 
3.4.2   Controls definition, selection criteria and collection  
3.4.2.1   Controls definition 
    The control subjects were TB patients who were treated with RHZE, either in combined or 
individual tablets, and who did not develop DILI during the same time frame, from 01 January 2013 
until 31 July 2017. 
 
3.4.2.2   Selection of controls 
3.4.2.2.1   Inclusion criteria 
    Controls were chosen if they had been treated regularly for TB in the same five referral TB clinics 
during the same period, for a minimum time on treatment of four months.        
    In the unlikely event of a control being registered on SITETB for any other reasons than DILI, 
he/she was still considered eligible in so far as they remained on the first-line regimen throughout 
treatment, even if in the following circumstances: if ethambutol was not prescribed (pediatric 
patients under ten years of age) or if they were discontinued for any reason; if tablets were 





individualized tablets of RHZE due to a previously identified risk factor for DILI, were also eligible as 
controls.     
 
3.4.2.2.2   Exclusion criteria 
    Patients with the following indications for registration on SITETB were ineligible as a control: 
mono-resistance to isoniazid or to rifampicin, or any non-DILI side effects leading to a disruption in 
the RHZ combination, such as untreatable gastro-intestinal intolerance to any of them; patients who 
had their treatment discontinued before completing 120 days, who were lost to follow-up for 
whatever reason or died before the 120th day of treatment; and patients with treatment irregularity, 
defined as taking treatment on less than 15 days in any 30 days period. All reasons for the exclusion 
of eligible controls were recorded. 
 
3.4.2.3   Controls collection  
    Candidates for the control group were obtained through the following process: by running a 
database search on the TB notifications in Porto Alegre from 2013 to 2017, classified by TB clinic 
and by year. In total they were 4,535 patients, on five separate Excel spreadsheets, extracted from 
the SINAN database of the General Coordination of Health Surveillance, CGVS. After scanning for 
duplicates, all potential controls were identified. Each one of the TB clinics had its own list, from 
which the control patients were selected by systematic sampling. Initially the following approach 
was used: after ordering the lists by year of notification, every third patient was selected and the 
corresponding medical record was then examined to ascertain if that patient fulfilled the criteria for 
being a control. If it was decided that the patient did not fulfil the criteria, the next patient was 
selected, and their medical records examined. In each clinic, the total number of controls produced 
was roughly four times the number of cases, by year. In the eventuality that any problems had 
happened in a certain year and clinic, for instance, a viral hepatitis outbreak in that clinic area, this 
measure would have made sure that cases and controls had been affected likewise.  
    At a certain point through data collection, during the first half of it, it was decided not to use the 
patients lists because they were incomplete, with missing patients and identification numbers, 
which prevented the investigator from having information on the year of treatment. Moreover, the 





3, the controls were selected directly from the medical records files, according to the same sampling 
system of every third patient. The TB clinics were dissimilar in their filing system. Table 1 shows their 
differences. 
 
Table 1.   Filing and storage systems in the TB clinics 
 
Classification system 
of medical records 
Storage order Deaths 
Clinic 1 
Year of start of 
treatment 
File ID number Included 
Clinic 2 
Year of start of 
treatment 
File ID number Included 
Clinic 3 
Year of start of 
treatment 
Patient’s first name in 
alphabetical order 
Excluded and stored 
separately 
Clinic 4 
Year of start of 
treatment 
File ID number Included 
Clinic 5 
Type of treatment 
(special treatments) 







3.5   Sample size and statistical power 
    From preliminary data, it was found that amongst patients on TB treatment, the prevalence of 
DM was 6.8% and among the cases (TB patients with DILI), it was 12.5%. The DM prevalence among 
cases of 12.5% was obtained from a pilot assessment of DILI cases in diabetic patients from the five 
main TB clinics in Porto Alegre. 
    The sample size needed to detect an odds ratio (OR) of 1.96, assuming a 1:3 ratio of cases: 
controls, a type I error of 5% and power of 80%, was approximately 244 cases and 730 controls. 
Nevertheless, the number of 244 cases was not reached during the pre-established study 
recruitment period from 1st January 2013 to 31st July 2017.  In an attempt to maintain the same 
power to detect the same measure of effect, the number of controls was increased to four to one 





size calculation for 90% power and a ratio of 1:4 for cases to controls, which would have required 
75 additional DILI cases, was also considered. Appendix K shows a table with the relationship 
between power and sample size for a range of effect sizes. 
 
3.6   Data collection methods 
3.6.1   Subjects 
    All data on subjects were collected from the patientsˈ medical records at the TB clinics and from 
electronic databases from the Brazilian PNCT. The PNCT notifies and monitors TB cases by way of 
two complementary information systems, the SINAN and the SITETB databases.   
  
3.6.2   Explanatory variables 
    The explanatory variables were collected from the SITETB electronic database, the SINAN form 
and from medical documentation. They are listed below. The main explanatory variable of interest 
was DM. The potential risk factors for DILI that were considered and recorded were age, sex, chronic 
hepatitis B and C infection; HIV infection, hazardous drinking, use of hepatotoxic drugs, other 
concomitant liver diseases and conditions; and site of TB. Other variables studied were method of 
TB diagnosis, method of DM diagnosis and, for cases, time to DILI. A literature search was performed 
in order to identify potential confounders. The covariates age, hazardous drinking, HCV and 
hepatotoxic drugs were previously identified as associated with both the exposure and the 
outcome.  
 
3.6.2.1   Age 
     The cases had their age calculated by subtracting the date of birth from the date of DILI diagnosis. 
In the eventuality of missing dates for DILI diagnosis, the date of start of RHZE was used for the age 
calculations. For the controls, age was derived by subtracting the date of birth from the date of start 
of RHZE. The calculations were done in the Excel database and presented in number of years; for 
children younger than 12 months old, they were recorded as being one year old. Subjects had their 





71 to maximum age. The reason for that was the large size of the sample and the fact that the 
literature concerned with risk factors for drug hepatotoxicity reports age in stratified age groups.   
 
 
3.6.2.2   Date of DILI 
    The date of DILI was defined as the earliest date of available liver tests showing abnormal results 
according to the standard definition of TB DILI (95): in the absence of symptoms, elevation of 
transaminases ≥ 5 times the ULN value; and in the presence of symptoms, ≥ 3 times the ULN value 
or twice the bilirubin ULN value. The variable was time to DILI and was calculated as the number of 
days from the start of treatment to the date of DILI, as defined here. In the eventuality of an 
unknown date, the closest probable date was used, taking into consideration any recorded date of 
symptoms together with liver tests.   
 
3.6.2.3   Date of SITETB 
    As a rule, the date of the notification onto SITETB is a few days after the patient has been on the 
new drug regimen, so that tolerance has been established. For the purposes of the present study, 
the final date for the DILI episode was 31 July 2017. It was noted by the researchers that patients 
may have been registered onto SITETB some days later than that. So, because of that time gap, 31 
August was the limit for capturing DILI cases on SITETB.       
 
3.6.2.4   TB Clinics 
    The five TB clinics participating in the study were given a number from one to five (Table 1): CRTB 
Centro, Clinic 1; CRTB Navegantes, Clinic 2; CRTB Vila dos Comerciários, Clinic 3; CRTB Bom Jesus, 
Clinic 4; and CRTB Hospital Sanatório Partenon, Clinic 5.   
 
3.6.2.5   TB diagnosis 
    Patients initiated on TB treatment included those with either a confirmatory microbiological 
diagnostic test or those who, despite lacking microbiological confirmation, had been commenced 





culture positive, a positive molecular biology method; and not confirmed, meaning a clinically 
diagnosed TB case. That would be a case which was not bacteriologically confirmed, but which was 
believed to be TB because of symptoms, imaging abnormalities and tests suggestive of Mtb infection 
taken all together into consideration. Culture was either in liquid or solid medium and molecular 
biology methods were Real Time quantitative PCR (qPCR) or GeneXpert® MTB/RIF assay.  In case 
there were positive results in more than one method (and only one possible record for the data 
capture sheet), a hierarchy of diagnostics was adopted. The gold standard was the culture, 
immediately followed by the molecular biology method and, lastly, the smear.  
 
3.6.2.6   Site of TB 
     This variable had three categories: only PTB, only EPTB and both PTB and EPTB. The latter was 
an attempt to reflect those with more extensive disease, and therefore, more severely ill patients. 
All TB sites were reported, and their frequencies analysed.  
 
3.6.2.7   Date of RHZE 
    The date of RHZE was the date of the start of treatment with isoniazid, rifampicin, pyrazinamide 
and ethambutol.    
 
3.6.2.8   DM 
    A patient was recorded as having DM if the diagnosis was reported according to the six categories 
provided for the DM diagnosis in this study. A patient was recorded as not having DM if a blood test 
confirmed its absence. In the case of an unconfirmed information of absence of DM, then it was 
recorded as unknown. In order to deal with missing data on DM, patients were classified either as 
known to have DM (with a confirmed DM diagnosis, according to the definitions below) or not 
known to have DM (DM status unknown or negative).  
DM diagnosis was defined as: 
• Definite DM diagnosis: 
    Established by the TB physician (or any other attending physician) at the outset of or 





Committee on the Diagnosis and Classification of Diabetes Mellitus (268) and from the 
International Expert Committee report on HbA1c (269): 
1.  HbA1c ≥ 6.5%; *  
or  
2.  a fasting plasma glucose ≥ 126 mg/dl. Fasting is defined as no caloric intake for at least eight 
hours*;  
or 
3.  a 2-hour plasma glucose ≥ 200 mg/dl during an oral glucose tolerance test (performed using 
a glucose load of 75g anhydrous glucose); * 
or 
4.  a random plasma glucose >200 mg/dl + classical symptoms (polyuria, polydipsia and 
polyphagia).  
    In the absence of unequivocal hyperglycaemia, the first three criteria (*) should be confirmed by 
a second test.  
• Probable DM diagnosis:    
    5. The patient informed a DM diagnosis prior to the TB episode associated with classical symptoms 
at the time of diagnosis, concomitant use of appropriate DM therapy (diet with or without 
pharmacological therapy) and follow-up;  
    or 
    6. The physician indicated in the paperwork that the patient had DM without evidence of the 
test criteria above.  
  
3.6.2.9   Hazardous alcohol use  
    Defined as a quantity or pattern of alcohol consumption that places patients at risk for adverse 
health events, as self-reported by the patient, their family or by the TB clinic team. Any reported 
use considered as hazardous was captured. There is a tendency for categorizing drinking habits 





the United States National Institute on Alcohol Abuse or Alcoholism (270), a hazardous habit is 
characterized as more than four drinks per day or 14 drinks per week for men; or more than three 
drinks per day or seven drinks per week for women. What was classified as abusive consumption 
encompassed hazardous drinking.   
    To deal with missing data on this variable, patients were classified either as known to be 
hazardous drinkers (a hazardous drinking pattern being reported by the patient or family) or not 
known to be hazardous drinkers (unknown status or a negative response).  
    
3.6.2.10   HIV, HCV and HBV  
    Patients with HIV, HCV and HBV positive status were captured from blood tests results, ordered 
by a physician, or from the rapid tests offered to all incident TB patients, as recommended by the 
PNCT protocol at the TB clinics. In order to deal with missing data on the tests results, patients were 
classified either as known to be HIV-, HCV- or HBV-positive (a positive test result) or not known to 
be HIV-, HCV- or HBV- positive (unknown test result or a negative result).  
 
3.6.2.11   Concomitant hepatotoxic drugs 
    All drugs were considered as taken, once prescribed by a physician, unless medical notes informed 
otherwise. All drugs prescribed concomitantly to RHZE were initially recorded on the data capture 
sheet, regardless of their potential for hepatotoxicity.  After that, they were searched for in the A 
and B lists published by Björnsson and Hoofnagle (271), as can be seen in Appendix C (tables C1 and 
C2) and only those were kept and used for statistical analyses. In case the records would not 
disclosure the exact period of the drug-taking, or if there was just a mention of the class name, for 
instance, nonsteroidal anti-inflammatory drugs or painkillers, then they were recorded as 
“unknown” and the drug class was noted, for completeness. 
    To deal with missing data on this variable, patients were classified either as known to have taken 
any concomitant hepatotoxic drugs if drugs were identified and the concomitance established; or 
not known to have taken hepatotoxic drugs if there was absence of drugs prescribed (interpreted as 






3.6.2.11.1   Reference for the classification of hepatotoxicity potential 
     Documentation of hepatotoxicity in the medical literature is variable and many published cases 
lack critical review. A standardized system for categorizing drugs implicated in causing liver injury 
was conducted by Einar S. Björnsson and Jay H. Hoofnagle (271), in which drugs were classified into 
categories of hepatotoxic potential according to a critical assessment based on the number of 
published reports of convincingly documented liver injury. Drugs described in the LiverTox® 
database (115) were classified into five categories based on the number of published cases 
(Category A, ≥ 50 cases; Category B, 12 - 49 cases; Category C, 4 - 11 cases; Category D, 1 - 3 cases; 
and Category E, none).   
    LiverTox® is a website on hepatotoxicity designed and supported by the National Institutes of 
Health of the United States Government. LiverTox® is a joint effort of the Liver Disease Research 
Branch of the National Institute of Diabetes and Digestive and Kidney Diseases and the Division of 
Specialized Information Services of the National Library of Medicine, National Institutes of Health. 
It provides updated, comprehensive and unbiased information about DILI caused by prescription 
and non-prescription drugs, herbal products, dietary supplements, and environmental toxins in 
general. It represents a collaborative effort by medical and scientific specialists to provide a 
collection of clinical information on the prevention and control of DILI.  By 2017, the LiverTox® 
website had more than 23,000 annotated references. 
    For the purposes of this study, drugs from categories A (≥ 50 cases) and B (12 - 49 cases) were 
reported as hepatotoxic (271). Their individual frequencies were reported and are shown in 
Appendix J.  
 
3.6.2.12   Other liver diseases 
    A patient was considered as having another liver disease or condition (apart from having chronic 
HCV or HBV) if that was made evident by an abdominal ultrasound or computerized tomography 
(CT) scan, liver biopsy or blood tests; or if there was any report from a physician to that effect. 
Patients were considered as not having another liver disease or condition if the above-mentioned 
tests proved its absence. Even in the absence of a conclusive diagnosis of a previous liver disease, 





a liver disease. All liver conditions were reported and their frequencies presented. Liver TB was 
included in this category.  
    To deal with missing data on this variable, patients were classified either as known to have another 
liver disease, if there was a definite diagnosis or strong suggestion of another liver disease; or not 
known to have another liver disease, if there was unconfirmed data on its absence or lack of any 
mention about it.   
 
3.6.2.13   Time elapsed before DILI 
    This variable was obtained by subtracting the date of start of RHZE from the date of DILI on the 
Excel database and reported in number of days.   
 
3.6.2.14   Other aspects 
    Data were also noted on TB clinic, pregnancy (being associated with liver tests abnormalities) and 
whether there had been any hospitalizations, in which case there could have been difficulties in data 
capturing, particularly if for long periods. 
 
3.6.3   Quality control of data collection  
    Quality control procedures were performed. In order to assess consistency, duplicate data 
extraction was performed on five records randomly selected, in the last week of data collection of 
each TB clinic. A 100% agreement was found between data extracted on two separate occasions, 
which were at least three weeks apart. All data extraction was undertaken by a single investigator 
(the candidate). Data were extracted from various sources: SINAN, SITETB (the only electronic one), 
medical records and TB clinic records (used mainly to check inconsistencies whenever necessary) 
and that made possible frequent quality checks. Not only did the diverse sources give information 
on the same variables (thus allowing to check data consistency) but provided complementary 






3.6.4   Data sources 
3.6.4.1   Outcome sources 
    The source for the outcome variable, DILI, was the SITETB database. Complementary information 
came from medical records in the TB clinics.  
 
3.6.4.1.1   SITETB Database 
    SITETB was the only data source for capturing the cases but, additionally, it provided clinical 
information on the explanatory variables.  Each TB clinic was scrutinized for DILI cases in the 
following way: all patients registered as of 1st January 2013 until the 31st August 2017 were 
examined as to their reason for having had a change of treatment. If it was due to hepatotoxicity or 
a previous liver disease, then all the data available on SITETB was reviewed. Cases registered as 
allergy or major intolerance were also examined, so as to capture any misclassified subjects. After 
all past cases had been examined, the TB clinics were assessed through SITETB for future incident 
cases every two weeks until 31st August 2017.  
 
3.6.4.1.2   Tuberculosis Notification Database 
    The Tuberculosis Notification Database, with information compiled from the TB Notification Form, 
the SINAN form, was initially chosen as the first source for the extraction of controls. Five lists were 
generated, one for each TB clinic, and stored as encrypted Excel spreadsheets. The filters for 
capturing the lists of patients from the Epidemiological Surveillance SINAN database are presented 
below. The filters included:  
1. Date of TB diagnosis: from 01/01/2013 to 31/07/2017; 
2. Follow-up clinics: all five CRTB – the TB referral clinics in Porto Alegre; 
3. Complete patient’s name; 
4. SINAN identification (ID) number; 
5. Medical record ID number; 
6. Date of birth;  





The filters excluded: 
1.  Patients with primary default; 
2. Patients who had a change of diagnosis any time after TB treatment was instituted.  
 
 












                          DILI: drug induced liver injury; DM: diabetes mellitus; HBV: hepatitis B virus; HCV: hepatitis C virus;  
                            HIV: human immunodeficiency virus; MR: medical records; RHZE: rifampicin, isoniazid, pyrazinamide  
                            and ethambutol; SINAN: Information System on Notifiable Diseases; SITETB: System of Information on  
                            Special Tuberculosis Treatments; TB: tuberculosis  
 
 
3.6.4.2   Exposure sources 
    Data on the main exposure, DM, was extracted from SITETB, the SINAN form and medical records, 
if it was a case; and from the SINAN form and medical records, if it was a control. Afterwards, all DM 















































































If a patient with DM was not reported as such on SITETB or SINAN, then the medical records review 
was able to clarify that. All the other variables were extracted from SITETB, SINAN, and medical 
documentation. In the eventuality that inconsistencies were found, the data from the physician’s 
notes on the medical records were always given preference and more credibility than the data from 
the SINAN form, SITETB or any other clinic report.  
 
3.6.5   Data Management 
    Firstly, a survey was created in an Excel file, shown in Appendix D. The project was named TBDM 
Project. It was then converted into an XML Open Data Kit (ODK) Form by using XLS Form Offline. This 
electronic data capture form was uploaded and stored in ODK@LSHTM, which is a fully encrypted 
Secure Sockets Layer (SSL) server. The SSL technology aims to securely establish an encrypted link 
between a server and a client. The electronic form was then transferred to a mobile phone where 
the data was collected and their records daily submitted to a database in the ODK server. The 
database was stored in ODK@LSHTM in a comma-separated values (CSV) text file.  In order to be 
managed and analyzed, the database was exported from the server, downloaded and stored safely 
in a password protected Excel file. It was subsequently cleaned, its variables coded, and fully 
prepared for the statistical analysis. Its security was assured as individual access to the database 
was granted solely to the study investigators. Personal identifiers were stripped and records were 
coded by record numbers. The file linking names with record numbers was securely stored 
separately in another encrypted Excel file. The subsequent statistical analysis required no personal 
identification details and was undertaken outside the study database.  
 
3.7   Statistical analysis 
    The categorical explanatory variables were cross-tabulated against case/control status. Crude 
(unadjusted) ORs for being a case and their associated 95% confidence intervals (CI) were calculated 
by logistic regression. Amongst controls, categorical explanatory variables were cross-tabulated 
with DM to help with the identification of confounders. Confounding and effect modification was 
initially explored using the Mantel-Haenszel (M-H) analysis, and subsequently using multivariable 





    In the M-H analysis confounders were identified if the adjusted OR for DM, after stratification, 
changed by at least 10% compared with the crude OR. Interactions were assessed with the Test of 
Homogeneity of ORs. The confounders identified were considered for the multivariable logistic 
regression. A priori, age group and sex were always adjusted for. Care was taken not to over-
parameterize the model: the maximum number of parameters (ORs) in the adjusted model was 
restricted to the total number of cases (157) divided by 10. 
    Initially a fully adjusted model was constructed without any interactions, giving a fully adjusted 
OR for the effect of known DM on being a case. Finally, interaction between variables and DM, 
adjusting for all variables currently in the model, was considered using logistic regression, based on 
effect modification observed in the M-H analysis. All the statistical analysis was undertaken in Stata® 
V.14 (StataCorp).   
   The time to DILI was defined as time from the TB treatment start to the date of DILI diagnosis, 
summarized as median and IQR, and displayed graphically using Kaplan-Meier curves stratified by 
DM status.  
 
3.8   Ethical considerations 
    Ethical approval was needed because this study is an analysis of routine human subject data 
obtained as part of clinical services which are not anonymized.  Permissions were sought from the 
London School of Hygiene and Tropical Medicine Research Ethics Committee (Appendix E) and from 
three Brazilian ethics committees, namely the Porto Alegre Municipal Health Department Research 
Ethics Committee, the Research Ethics Committee of the School of Public Health of the State of Rio 
Grande do Sul Health Department, and the National Commission for Research Ethics, a commission 
of the National Health Council, so that unrestricted access to medical records and databases may 
be granted. First, it was necessary to obtain the local approval from two coordinators of the 
Municipal Department of Health of Porto Alegre, namely from the General Coordination of 
Specialized Care (CGAE), for permission to have access to medical records at the four municipal TB 
clinics; and from the General Coordination of Health Surveillance (CGVS), in order to have access to 
the TB Notifications Database. A third permission was granted by the Hospital Sanatório Partenon, 
for access to the medical records at the fifth TB clinic, the hospital clinic. Once these three local 





platform in which all research ethics committees have access to research projects in order to analyze 
them and report their decisions. Through Plataforma Brasil, the Porto Alegre Municipal Health 
Department Research Ethics Committee; the Research Ethics Committee of the School of Public 
Health of the State of Rio Grande do Sul Health Department; and the National Commission for 
Research Ethics, granted their final approvals for the study. All the Brazilian ethics approval 
documentation may be seen in Appendices F to I, beginning with the final approval from the 
National Commission for Research Ethics and ending with the local approvals.   
    The investigators were allowed access to patient identified data without seeking patients’ 
permission. According to the Normative Resolution nº 466/2012 from the National Health Council, 
the use of the Informed Consent Form was waivered because this was an observational study that 
analyzed data from medical records, institutional databases and additional data sources available in 
those institutions without biological material involvement; because all data was to be managed and 
studied anonymously; the results were to be presented anonymously in an aggregated way; and 
because it was a retrospective and non-interventional design with no interference on the routine 
care of the study subjects and, consequently, without any harm to their welfare.       
    All data were stored safely in a password-protected Excel file and also in the ODK server. Their 
security was assured as individual access to the database was granted solely to the study 
investigators. Personal identifiers were deleted and records were coded by record numbers; the file 
linking names with record numbers was securely stored separately. The subsequent statistical 












CHAPTER 4  -  RESULTS  
 
4.1   Patients characteristics and univariate analysis 
4.1.1   Patients characteristics 
    A total of 791 subjects with active TB and treated with RHZE between 1st January 2013 and 31st 
July were included in the study, 157 DILI cases and 634 controls.  
 
4.1.1.1   Cases 
4.1.1.1.1   Exclusions of cases 
    All DILI cases satisfying the inclusion criteria for this study were eligible and captured from the 
SITETB database. There were five patients with DILI who were started on treatment and registered 
on SITETB while in hospital, but who defaulted immediately after being discharged, never registering 
in any TB clinic. As a result, they were excluded due to loss to follow-up up in a TB clinic, which 
rendered them ineligible because of lack of medical documentation.  One patient was excluded due 
to his TB regimen including rifabutin instead of rifampicin. He was an HIV and HCV positive individual 
who was also a hazardous drinker taking concomitant hepatotoxic drugs. No patients with DM were 
excluded among the DILI cases.  
 
4.1.1.1.2   Cases characteristics 
    Amongst the DILI cases, the prevalence of known DM was 10.8%. The DILI patients’ age ranged 
from 1 year to 93 years old, with a median of 46 years (IQR 37 - 60). The majority of patients (32.5%) 
were in the youngest age group, being patients under 40 years old. Most patients were males 
(61.2%). One third (33.1%) of the cases were hazardous drinkers, and nearly half (49.7%) were HIV-
positive; 22.9% were HCV infected and 3.2% were HBV infected. (Table 5). 
    As can be seen in Appendix J, Table J1, hepatotoxic drugs were taken concomitantly by more than 
half of the cases (59.9%). All drugs known to be potentially hepatotoxic, according to the literature 





the cases were efavirenz and sulfamethoxazole associated with trimethoprim, both with a 29.8% 
(28/94) prevalence, followed by omeprazole (19.1%; 18/94) and fluconazole (10.6%; 10/94).     
    Other concomitant liver diseases and any liver-affecting conditions were found in as few as 14% 
of cases and are displayed in Table 3. Cirrhosis was the most prevalent liver disease, half of the 
patients were cirrhotic (50%); the second most prevalent disease was liver TB (13.6%).  
 
 
Table 3. Other liver diseases in cases and controls 
Liver disease 
        Cases (n=22) 
Frequency         %       
Controls (n=16) 
Frequency          % 
Cirrhosis 11 50 0 0 
Liver TB 3 13.6 6 37.5 
Congestive heart failure 1 4.5 3 18.8 
Others* 6 27.3 6 37.5 
Unknown  2 9.1 1 6.3 
                      
                     TB: tuberculosis 
                * Cases: Alcoholic liver disease but not cirrhotic (1), steatosis (1), lithiasis (1),  
                granulomatous hepatitis (1), Systemic Lupus Erythematosus (1) and choledocoli- 
                thiasis (1). One patient had cirrhosis and congestive heart failure concomitantly. 
                * Controls: Alcoholic liver disease but not cirrhotic (2), steatosis (1), autoimmune 
                hepatitis (1), liver metastasis (1), non-alcoholic steatohepatitis (1). 
                 
 
 
    Extrapulmonary TB sites were found in 45.9% of the DILI cases (n=72) (Tables 4 and 5).  A little 
over half of the cases had only PTB (54.1%), and nearly one third (31.2%) had both PTB and 
EPTB. As detailed in Table 4, both the pleura and lymph nodes were the most prevalent sites 







Table 4. Extrapulmonary TB sites (not mutually exclusive) in cases and controls   
 
 
                CNS: central nervous system 
                ** Cases: peritoneum (4), bone marrow (3), testicle (2), pericardium (1), bone (1),  
                kidney (1) and psoas (1). 
                ** Controls: eye (7), pericardium (6), peritoneum (5), testicle (3), bone (2), skin  
                (2), joint (1), kidney (1), bladder (1), ureter (1), oesophagus (1), larynx (1), pharynx  
                (1), vertebrae (1), intervertebral disc (1), thoracic wall (1) and bone marrow (1).     
 
     
    Of the 157 cases, the time to DILI diagnosis was observed in 152 patients; five cases could not 
have their DILI dates identified. The median time to DILI was 17.5 days (IQR 9.5 – 49). In the group 
with known DM, it was 23.5 days (IQR 12.5 – 45.5) and among those without DM, it was 17 days 
(IQR 9 – 50). There was no difference in the time to DILI between patients with and without known 









Frequency           % 
Controls (n=214) 
Frequency           % 
Pleura 30 41.7 112 52.3 
Lymph nodes 30 41.7 65 30.4 
CNS 9 12.5 17 7.9 
Liver 6 8.3 8 3.7 
Intestine 5 6.9 3 1.4 
Spleen 2 2.8 8 3.7 
Others** 13 18.1 36 16.8 





Figure 1. Kaplan-Meier curves for time to DILI, stratified by DM status 
 
DILI: drug induced liver injury; DM: diabetes mellitus 
 
     
    There were no deaths over the course of TB treatment amongst the DILI cases, nor patients who 
were lost to follow-up at any point in their treatment. None of the DILI cases were pregnant over 
the course of TB treatment.   
 
4.1.1.2   Controls 
4.1.1.2.1   Exclusions of controls 
    Of the 749 medical records reviewed, 634 patients satisfied the screening criteria for being a 
control. Of the 115 patients who did not meet the screening criteria, 54 (46.9%) were due to loss to 
follow-up (defined as missing > 30 days of treatment) before completing at least four months of 
treatment; 15 (13%) were transferred before the 4th month of treatment; ten (8.7%) died before the 





changed (reasons including skin allergy and gastrointestinal intolerance); three (2.6%) were 
excluded because of their extremely prolonged time in hospital, precluding access to reliable data 
on drugs; 13 (11.3%) patients experienced irregularity of treatment (taking treatment on ≤ 15 days 
in any 30 days period); four (3.5%) and three (2.6%) had missing or illegible medical records, 
respectively. One male patient was excluded because he was taking rifabutin instead of rifampicin. 
He was HIV positive and was also taking concomitant hepatotoxic drugs. No controls with DM were 
excluded. 
  
4.1.1.2.2   Controls characteristics  
    Amongst the 634 controls, 9.9% had known DM. The patients’ age ranged from three months to 
93 years old, with a median of 37 years (IQR 25 - 50). The majority of patients (55.8%) were in the 
youngest age group of less than 40 years old. Most patients were males (55.4%). As much as 17% 
were hazardous drinkers; HIV prevalence was 21.8%, while 5.7% and 0.3% had HCV and HBV 
infection, respectively. 
    Hepatotoxic drugs were taken concomitantly by nearly half of the controls (48.6%). The most 
prevalent hepatotoxic drugs among the controls were omeprazole (32.5%), efavirenz (19.5%) and 
sulfamethoxazole associated with trimethoprim, (16.9%), as shown in Appendix J, Table J1. Other 
concomitant liver diseases or conditions were found in 16 (2.5%) controls (Table 5). Liver TB (37.5%) 
was the most prevalent liver disease among controls, followed by congestive heart failure (18.8%) 
(Table 3).  
    Two thirds (66.3%) of the controls had only PTB, while EPTB sites were found in one third (33.8%; 
n=214), either associated or not to PTB (Table 5). The most common EPTB sites were pleura (52.3%) 
and lymph nodes (30.4%), followed by CNS (7.9%) (Table 4). 
    There were 8 pregnant control patients during the course of their TB treatment, of whom one 
was diagnosed with intra-hepatic cholestasis of pregnancy.  
    Cross tabulations are shown in Table 5, which includes and additional column indicating 
separately the characteristics of the subgroup of controls with known DM. The DM prevalence was 
similar by sex (10.3%; 36/351 vs. 9.5%; 27/283), hazardous drinking and HCV. Diabetes prevalence 
increased with increasing age. Those patients between 61 and 70 years of age had the highest 





negatives (3.6% vs 11.7%) and none of those who were HBV-positive had DM. Diabetes prevalence 
was higher among those taking other hepatotoxic drugs versus not (15.9% vs. 4.3%), and slightly 
higher among those with other liver diseases versus without other liver diseases (12.5% vs 9.9%). 
Diabetes prevalence was highest among those with PTB only (13.1%; 55/420).    
 
 












Univariate analysis comparing cases 
with controls 






Known DM     
No 140 89.2 571 90.1     
Yes 17 10.8 63 9.9  1.10 0.62 - 1.94 0.7 
Age group (in years)   1.51** 1.30 - 1.74 < 0.001 
1* - 39 51 32.5 354 55.8 9 2.5 1  
< 0.001 
40 – 50 43 27.4 127 20.0 19 15.0 2.35 1.49 - 3.70 
51 – 60 24 15.3 74 11.7 12 16.2 2.25 1.30 - 3.89 
61 – 70 22 14.0 61 9.6 18 29.5 2.50 1.42 - 4.42 
71 – 93 17 10.8 18 2.8 5 27.8 6.56 3.18- 13.53 
Sex   
 
  
Male 96 61.2 351 55.4 36 10.3 1   
Female 61 38.9 283 44.6 27 9.5 0.79 0.55 - 1.13 0.2 
Hazardous drinking   
 
  
No 105 66.9 526 83.0 51 9.7 1   
Yes 52 33.1 108 17.0 12 11.1 2.41 1.62 - 3.59 < 0.001 
Known HIV infection   
 
  
No 79 50.3 496 78.2 58 11.7 1   
Yes 78 49.7 138 21.8 5 3.6 3.55 2.43 - 5.18 < 0.001 
Known HCV infection   
 
  
No 121 77.1 598 94.3 59 9.9 1   
Yes 36 22.9 36 5.7 4 11.1 4.94 2.95 - 8.29 < 0.001 
Known HBV infection   
 
  
No 152 96.8 632 99.7 63 10.0 1   
Yes 5 3.2 2 0.3 0 0 10.39 1.97 - 54.83 0.003 








* The youngest patient was 3 months old; median age among cases was 46 years old (IQR 37 – 60);  
median age among controls was 37 years old (IQR 25 – 50) 
** OR based on assumed linear trend; P-value based on Score test for trend. No evidence for departure  
from linearity (P = 0.3) 
P-values for the Likelihood Ratio test 
Col: column; CI: Confidence Interval; DM: diabetes mellitus; EPTB: extrapulmonary tuberculosis; HBV: he- 
patitis B virus; HCV: hepatitis C virus; HIV: immunodeficiency virus; IQR interquartile range; OR: odds ratio; 
PTB: pulmonary tuberculosis; TB: tuberculosis  
 
         
4.1.2   Univariate analysis 
    Diabetes prevalence was similar in cases and controls (10.8% vs. 9.9%, respectively), giving an 
unadjusted OR of 1.10 (95% CI 0.62 - 1.94; P = 0.7) (Table 5).  DILI cases tended to be older than 
controls, as a group (median 46 years; IQR 37 – 60 vs. median 37 years IQR 25 – 50). There was 
strong evidence that increasing age was associated with increased odds of DILI (P for trend <0.001), 
suggesting a 1.5-fold increase in odds of DILI for a unit increase in age-band (OR 1.51; 95% CI 1.30 - 
1.74). There was no evidence of differences in sex distribution; 38.9% females in cases versus 44.6% 
females in controls (unadjusted OR 0.79; 95% CI 0.55 - 1.13; P = 0.2).  
    Compared to TB patients not experiencing DILI (controls), TB patients experiencing DILI (cases) 
had two and a half times the odds of being hazardous drinkers (unadjusted OR 2.41; 95% CI 1.62 - 
3.59; P < 0.001). Compared to TB patients not experiencing DILI, TB patients experiencing DILI had 
nearly four times the odds of being HIV co-infected (OR 3.55; 95% CI 2.43 - 5.18; P < 0.001); five 
times the odds of having HCV infection (OR 4.94; 95% CI 2.95 - 8.29; P < 0.001); and 10 times the 
No 63 40.1 326 51.4 14 4.3 1   
Yes 94 59.9 308 48.6 49 15.9 1.58 1.11 - 2.26 0.01 
Known other liver diseases   
 
  
No 135 86.0 618 97.5 61 9.9 1   
Yes 22 14.0 16 2.5 2 12.5 6.29 3.17 - 12.51 < 0.001 
TB site   
 
  
Only PTB 85 54.1 420 66.3 55 13.1 1  
 
< 0.001 
Only EPTB 23 14.7 145 22.9 6 4.1 0.78 0.48 - 1.29 





odds of having HBV infection (OR 10.39; 95% CI 1.97 - 54.83; P = 0.003). Compared to TB patients 
without DILI, those who had DILI had one and a half times the odds of having taken hepatotoxic 
drugs concomitantly with RHZE (OR 1.58; 95% CI 1.11 - 2.26; P = 0.01). DILI cases were found to 
present a substantially higher prevalence of concomitant other liver diseases or transaminases-
altering conditions (14% vs. 2.5%; P < 0.001). The univariate analysis showed that DILI patients were 
six times as likely to have another liver disease or condition as those without DILI (OR 6.29; 95% CI 
3.17 - 12.51; P < 0.001). It was demonstrated that DILI patients, were compared to controls, were 
three and a half times more likely to have both PTB and EPTB than only PTB (OR 3.51; 95% CI 2.27 - 
5.42; P < 0.001); and there was no evidence that DILI patients, when compared to controls, had 
increased odds of having only EPTB (OR 0.78; 95% CI 0.48 - 1.29; P = 0.34) when compared to only 
PTB.  
 
4.2   Bivariate analysis 
4.2.1   Confounding 




Table 6. Odds Ratios for the effect of DM on DILI, after adjustment for potential 
confounding variables, individually 
Stratified by: 
Adjusted OR for known 
DM (95% CI) 




Age 0.72           (0.40 - 1.31) 0.9 
Sex 1.09           (0.62 - 1.93) 0.9 
Hazardous drinking 1.02           (0.57 - 1.81)   0.09 
HIV 1.44           (0.80 - 2.60) 0.7 






    
 
                     
 
                   CI: confidence interval; DM: diabetes mellitus; EPTB: extrapulmonary tuberculosis; HBV: 
                   hepatitis B virus; HCV: hepatitis C virus; HIV: human immunodeficiency virus; OR: odds 
                   ratio; PTB: pulmonary tuberculosis; TB: tuberculosis 
                   * Adjusted analysis could not be undertaken due to sparsity of data. 
 
     
    Individually, sex, hazardous drinking, HBV and other liver diseases, did not appear to confound 
any effect of DM on the odds of DILI. The following covariates: age (DM M-H OR 0.72; 95% CI 0.40 - 
1.31), HIV (DM M-H OR 1.44; 95% CI 0.80 - 2.60), and TB site (DM M-H OR 1.29; 95% CI 0.72 - 2.32), 
presented as confounders on the effect of DM on DILI.  
    Bivariate analysis to explore the effect of HBV on the DM OR for DILI was not conducted due to 
sparse data (7 patients in total).  Similarly, there were no patients with DM in the only EPTB stratum 
among the DILI cases.    
 
4.2.2   Effect modification 
     After controlling for HCV infection, the effect of DM on DILI became slightly smaller (OR 0.93; 
95% CI 0.49 - 1.75), showing a possible confounding effect of HCV. There was, however, weak 
evidence for HCV modifying the effect of DM on DILI (P = 0.06). Likewise, there was evidence that 
concomitant use of hepatotoxic drugs modified the effect of DM on DILI (P = 0.01). These two 
interactions will be considered in more detail in the multivariable regression model. 
    
HBV * - - 
Hepatotoxic drugs 0.98           (0.55 - 1.75)   0.01 
Other liver diseases 1.14           (0.64 - 2.03) 0.3 





4.3   Multivariate analysis 
4.3.1   Adjusted model without interaction 
     A multivariate logistic regression analysis was performed to obtain a fully adjusted OR for the 
effect of DM on DILI (Table 7). The fully adjusted model controlled for age, HIV and TB site as all 
were identified as important confounders in the Mantel-Haenszel analysis. The sex variable was 
included in the model, a priori. In addition, HCV and hepatotoxic drugs were included in the model 
for completeness as they will be assessed as effect modifiers in section 4.3.2 and 4.3.3. 
    The adjusted OR for DM was 0.88 (95% CI 0.45-1.71; P = 0.7). Even though the modelling strategy 
was not based on assessing the causal effect of other variables on DILI, it was noted that the 
following variables were strongly associated with DILI: increasing age (P < 0.001); being HIV-positive 
(P < 0.001); having HCV infection (P < 0.001); and having more extensive disease, defined as both 
PTB and EPTB (vs. only PTB;  P< 0.001). 
  
 
Table 7. Multivariate logistic regression. Fully adjusted analysis of the model                
without interactions between the exposure variables (n=791) 





P - value 
 
Known DM  
No  1   
Yes 0.88 0.45 - 1.71 0.7 
Age group (in years)  
      1 - 39* 1  
< 0.001 
                                40 - 50  1.69 1.00 - 2.86 
                                51 - 60 2.39 1.30 - 4.38 
                                61 - 70 4.37 2.28 - 8.35 
                                71 - 93 12.91 5.81 - 28.66 
Sex  
Male 1   
Female 1.09 0.72 - 1.63 0.7 
Known HIV infection  





Yes 3.59 2.25 - 5.73 < 0.001 
Known HCV infection  
No 1   
Yes 3.49 1.96 - 6.21 < 0.001 
Known Hepatotoxic drugs  
                                        No 1   
                                       Yes 0.84 0.54 - 1.29 0.4 
TB site  
Only PTB 1   
< 0.001 Only EPTB 0.75 0.43 - 1.30 
PTB and EPTB 3.16 1.93 - 5.19 
 
                 * The youngest patient was 3 months old   
                   P-value for the Likelihood Ratio test 
CI: confidence interval; DILI: drug induced liver injury; DM: diabetes mellitus; EPTB: ex- 
trapulmonary tuberculosis; HBV: hepatitis B virus; HCV: hepatitis C virus; HIV: human 
immunodeficiency virus; OR: odds ratio; PTB: pulmonary tuberculosis; TB: tuberculosis 
 
4.3.2   Interaction between DM and hepatotoxic drugs 
    After adjusting for age, sex, HIV, HCV and TB site, there was not strong evidence for an interaction 
between hepatotoxic drugs and DM on DILI (P value for the interaction = 0.1). The stratum specific 
ORs for DM were 1.78 (95% CI 0.62 - 5.12) among those taking no hepatotoxic drugs, and 0.61 (95% 
CI 0.26 – 1.40) among those taking hepatotoxic drugs (Table 8). Note that in the no hepatotoxic 
drugs stratum there were only 7 cases with DM.  
 
 
Table 8. Interaction between DM and hepatotoxic drugs, adjusted for age, sex, HIV,  
HCV and TB site. P-value for the interaction = 0.1 
Odds of DILI by known 


















         








             
             * adjusting for age, sex, HIV, HCV and TB site 
             CI: confidence interval; col: column; DILI: drug induced liver injury; DM: diabetes mellitus; OR:  
             odds ratio 
 
 
4.3.3   Interaction between DM and HCV 
    After adjusting for age, sex, HIV, use of hepatotoxic drugs and TB site, there was some evidence 
that HCV modified the effect of DM on DILI (P value for the interaction = 0.02; Table 9). There was 
no definite evidence of an association between having DM and increase in odds of DILI among those 
with HCV (OR 3.37; 95% CI 0.86 - 13.16; P = 0.08). Likewise, there was no definite evidence of an 
association between having DM and a 46% reduction in odds of DILI among those without HCV (OR 
0.54; 95% CI 0.23 - 1.26; P = 0.2). It is also noted in both strata that there are three DM cells with 
less than ten individuals, so analyses should be treated with caution.   
 
 
Table 9. Adjusted effect of DM stratified by HCV status, adjusted for age, sex, HIV, 
hepatotoxic drugs and TB site. P-value for the interaction = 0.02 
Odds of DILI by known 









95% CI P- value 

























































3.37 0.86 - 13.16 0.08 
         
        * adjusting for sex, age, hepatotoxic drugs, HIV, and TB site  
        CI: confidence interval; col: column; DILI: drug induced liver injury; DM: diabetes mellitus; HCV: he- 
        patitis C virus; OR: odds ratio 
 
    
    To conclude, from the present fully adjusted analysis for presenting an OR for DM on DILI (Table 
7), it was shown that DM did not increase the odds of having TB DILI. Similarly, other variables such 
as sex, taking other hepatotoxic drugs and having only EPTB (when compared to only PTB) were not 
associated with increased odds of DILI. Age over 50 years old, HIV infection, HCV infection and 
having both PTB and EPTB (when compared to only PTB) were shown to independently increase the 
odds of having TB DILI. There was some evidence that HCV infection acted as effect modifier on the 
effect of DM on DILI, although that finding should be interpreted with caution. Having DM was 
associated with not statistically significant increased odds of DILI among those with HCV infection, 
and not statistically significant reduction in odds of DILI among those without HCV infection.  
 
4.4  Missing data  
    Missing data was tabulated and presented as follows. It can be surmised from Table 10 that for a 
number of the variables the missingness is significantly different between cases and controls, and 
usually greater in controls. The main exposure (DM) had 10.3% missing data among controls and 
only 2.6% amongst cases. The percentage with missing data for hazardous drinking and HIV was 
extremely low (<1.5%). Missing data for HCV, HBV and other liver diseases was high, with the 
percentage missing data amongst controls much higher than amongst cases. With hepatotoxic 
drugs, unlike the other exposures, missing data was higher amongst the cases (18.5%) than controls 








 Table 10. Variables with missing data (n=791)  
 Cases           
N (%) 
Controls         
N (%) P value* 
DM    
No 136 (86.6%) 506 (79.1%) 
0.002 Yes 17 (10.8%) 63 (9.9%) 
Missing 4 (2.6%) 65 (10.3%) 
Hazardous drinking     
No 103 (65.6%) 526 (83.0%) 
0.004 Yes 52 (33.1%) 108 (17.0%) 
Missing 2 (1.3%) 0 (0%) 
HIV    
No 78 (49.7%) 492 (77.6%) 
> 0.99 Yes 78 (49.7%) 138 (21.8%) 
Missing 1 (0.6%) 4 (0.6%) 
HCV    
No 93 (59.2%) 387 (61.0%) 
< 0.001 Yes 36 (22.9%) 36 (5.7%) 
Missing 28 (17.8%) 211 (33.3%) 
HBV    
No 108 (68.8%) 342 (53.9%) 
< 0.001 Yes 5 (2.2%) 2 (0.3%) 
Missing 44 (28.0%) 290 (45.7%) 
Hepatotoxic drugs    
No 34 (21.7%) 288 (45.4%) 
< 0.001 Yes 94 (59.9%) 308 (48.6%) 









*P value for the association between whether the variable has missing 
data and the outcome (case/control status) 
DM: diabetes mellitus; HBV: hepatitis B virus; HCV: hepatitis C virus;  
HIV: Human immunodeficiency virus 
      
Comparing the original univariate analysis and the one conducted excluding records with 
missing data (Table 11), the measures of effect showed slightly decreased (closer to 1), albeit very 
similar effect sizes, except for hepatotoxic drugs, which presented with an increase in OR. 
 
 
Table 11. Complete case analysis (varying sample sizes) compared with original analysis (n= 791) 
- Univariate analysis 
Variables with 















1.0     
 (0.57 - 1.77) 
>0.99 
1.10 


















 (1.66 - 3.64) 
<0.001 
2.41 
















3.57   
(2.47 - 5.14) 
<0.001 
3.55 

















 (2.49 - 6.96) 
<0.001 
4.94 











Other liver diseases    
No 105 (66.9%) 325 (51.3%) 
< 0.001 Yes 22 (14.0%) 16 (2.5%) 











 (1.51- 41.39) 
0.01 
10.39 







































 (2.16 -8.41) 
<0.001 
6.29 












* where missing data were grouped with the “no” category 
CI: confidence interval; DM: diabetes mellitus; HBV: hepatitis B virus; HCV: hepatitis C virus; HIV: human 
immunodeficiency virus; OR: odds ratio  
     
     
    The fully adjusted analysis excluding the missing data presented measures of effect sizes very 
similar to the original multivariate analysis (Table 12). In the 51 – 60 age group, HCV and having 
both PTB and EPTB, the ORs are a little smaller (2.39 vs. 1.56; 3.49 vs. 2.81 and 3.16 vs. 2.54, 
respectively), but CIs overlap so results are broadly similar. The P values that achieved 
significance levels in the original analysis remained as such, as were the ones that did not (0.2 
for DM, 0.4 for sex and 0.9 for hepatotoxic drugs).  
 
 
Table 12. Fully adjusted complete case analysis (n =482; 104 cases and 378 controls) and from 





















DM     
No  1      
Yes 0.57 0.23 – 1.41 0.2 0.88 0.45 – 1.71 0.7 









40 - 50 1.66 0.89 – 3.09 1.69 1.00 – 2.86 
51 - 60 1.56 0.70 – 3.48 2.39 1.30 – 4.38 
61 - 70 4.86 2.16 – 10.95 4.37 2.28 – 8.35 
71 - 93 11.53 3.82 – 34.79 12.91 5.81 – 28.66 
Sex     
Male 1      
Female 1.24 0.76 – 2.05 0.4 1.09 0.72 – 1.63 0.7 
HIV      
No 1      
Yes 3.42 1.87 – 6.26 <0.001 3.59 2.25 – 5.73 <0.001 
HCV      
No 1      
Yes 2.81 1.43 – 5.50 0.003 3.49 1.96 – 6.21 <0.001 
Hepatotoxic drugs     
No 1      
Yes 0.95 0.50 – 1.80 0.9 0.84 0.54 – 1.29 0.4 
TB site     





Only EPTB 0.66 0.33 – 1.30 0.75 0.43 – 1.30 
PTB and 
EPTB 
2.54 1.40 – 4.62 3.16 1.93 – 5.19 
 
*P value for the likelihood ratio test 
CI: confidence interval; DILI: drug induced liver injury; DM: diabetes mellitus; EPTB: extrapulmonary 
tuberculosis; HCV: hepatitis C virus; HIV: human immunodeficiency virus; OR: odds ratio; PTB: pulmonary 
tuberculosis; TB: tuberculosis 
 
     
    Due to the case-control study design, further exploration of missingness was performed 
separately amongst cases and controls. Amongst the controls (Table 13): in relation to age, the 
missingness of data for HCV, HBV, hepatotoxic drugs and other liver diseases was similar across age 
groups, whereas for DM, missingness was more common for those aged <50 year. For those >50 
years of age, the proportion of missing data decreased.  The proportion of missing data for DM, HCV, 
HBV, hepatotoxic drugs and other liver diseases was similar for males and females. In the TB site 









              Table 13. Cross tabulations between variables with and without missing data amongst the control 


















Total number of controls  
N = 634 
N = 65  
(10.2%) 
N = 211  
(33.3%) 
N = 290 
(45.7%) 
N = 38 
(6.0%) 










































































































































               DM: diabetes mellitus; EPTB: extrapulmonary tuberculosis; HBV: hepatitis B virus; HCV: hepatitis C virus;  
               PTB: pulmonary tuberculosis; TB: tuberculosis 
 
 
    Amongst the cases (Table 14), missing data differs between sexes, with males showing more missing data 





although not for DM. In terms of the three categories for TB site, it can be observed that missing data for 
HCV, HBV was higher in only PTB; for DM it was higher in only EPTB; and for hepatotoxic drugs and other 
liver diseases, it was higher in the both PTB and EPTB category.   
 
 















for other liver 
diseases 
Total number of cases 
 N = 157 
N = 4 
(2.5%) 
N = 28 
(17.8%) 
N = 44 
(28%) 
N = 29 
(18.5%) 
N = 30 
(19.1%) 
      Explanatory 
variables 














  1 - 39 51 0 (0%) 7 (13.7%) 9 (17.6%) 8 (15.7%) 12 (23.5%) 
40 - 50 43 0 (0%) 4 (9.3%) 12 (27.9%) 7 (16.3%) 4 (9.3%) 
51 - 60 24 3 (12.5%) 5 (20.8%) 9 (37.5%) 6 (25.0%) 4 (16.7%) 
61 - 70 22 1 (4.5%) 6 (27.3%) 7 (31.8%) 4 (18.2%) 6 (27.3%) 
71 - 93 17 0 (0%) 6 (35.3%) 7 (41.2%) 4 (23.5%) 4 (23.5%) 
        
Sex 
Male 96 4 (4.2%) 19 (19.8%) 31 (32.3%) 20 (20.8%) 20 (20.8%) 
Female 61 0 (0%) 9 (14.8%) 13 (21.3%) 9 (14.7%) 10 (16.4%) 
        
TB 
site 
Only PTB 85 2 (2.4%) 19 (22.4%) 30 (35.3%) 14 (16.5%) 15 (17.6%) 
Only 
EPTB 
23 1 (4.4%) 2 (8.7%) 5 (21.7%) 4 (17.4%) 3 (12.0%) 
PTB and 
EPTB 
49 1 (2.5%) 7 (14.3%) 9 (18.4%) 11 (22.5%) 12 (24.5%) 
 
DM: diabetes mellitus; EPTB: extrapulmonary tuberculosis; HBV: hepatitis B virus; HCV: hepatitis C virus; 
PTB: pulmonary tuberculosis; TB: tuberculosis 
 
 







CHAPTER 5  -  DISCUSSION  
 
    Tuberculosis remains to be a major health problem globally. Short-course therapy with RHZE has 
proven to be highly effective but it is not without difficulties. DILI is its most serious adverse effect, 
leading to considerable morbidity and mortality through non-adherence and eventual default from 
treatment. It may also lead to failure, relapse and the most dreaded consequence, drug resistance 
(272). It can also cause acute liver failure, resulting either in liver transplant or death. These negative 
outcomes result in significant impairment on the effectiveness of any TB control programme. The 
need for a change of treatment means less efficacious and longer-lasting drug regimens, thus 
maintaining a favourable scenario for default from treatment and perpetuating the cycle of TB 
transmission. In the end, the most serious risk factor for a negative outcome of a DILI case is 
inadvertent continuation of therapy (148). Hepatotoxicity due to TB DILI can be fatal and mortality 
can reach up to 27% (273, 274). Identifying such episodes early on plays a major role in mitigating 
the extent of liver injury by allowing for discontinuation of the drugs.  
    Previous studies have analysed monitoring strategies and shown that they can be beneficial in 
terms of improving outcomes (95, 173, 275-279). DILI may remain hidden during preclinical and 
clinical phases of drug development. Besides, post-marketing studies frequently enrol insufficient 
numbers of individuals to be able to detect hepatotoxicity, before launching drugs in the market to 
be prescribed to thousands of patients. Epidemiological data from DILI in the literature comes from 
reports of either isolated cases or small series of cases. Therefore, the creation of an information 
archive system for DILI cases is vital for quantifying the degree of association and rigorous 
assessment of causality. 
    Monitoring is effective but costly, and the literature reports many risks factors for DILI. It should 
be noted that the risk of development of DILI has been shown to increase in the presence of one or 
more of specific risk factors (280). Some well-known risk factors include old age (124, 130, 136, 138, 
148, 152, 153, 281-283), female sex (95, 106, 137, 138, 150, 153-155, 164, 275, 283-306), HIV 
infection (88, 90, 92, 156, 164, 307-311), HCV infection (88, 90, 92, 154, 301, 307-310, 312, 313), 
HBV infection (88, 90, 92, 147, 154, 300, 307-310), pre-existent liver disease (95), alcohol 
consumption (81, 92, 124, 127, 130, 137, 143, 147, 148, 152-154, 164, 280, 282, 299, 306, 307, 312, 
314-320), concomitant use of other hepatotoxic drugs (321-326), malnutrition (124, 153-155, 164, 





and genetic factors (284, 332). However, these well-established and other potential risk factors, 
such as tobacco smoking (333), are still being explored by researchers worldwide. 
    As far as could be ascertained, no study has hypothesized an association between DM and DILI 
and studied it as an independent risk factor for DILI. Thus, a retrospective case-control study of TB 
patients who developed DILI severe enough to need a change of regimen during treatment with 
RHZE was conducted in Porto Alegre, Brazil, between January 2013 and July 2017. Patients with DILI 
were identified from the national electronic database SITETB and controls were captured from the 
municipal notification database and clinic records. For each case, 4 patients treated with the same 
drug regimen during the same period (2013 to 2017) and who did not develop DILI, were selected 
as controls.  
    It was sought to determine whether DM is associated with an increased risk of TB DILI and to 
further study any risk factors associated with the DM effect on DILI. From the present fully adjusted 
analysis, it was seen that DM was not associated with increased odds of DILI. Likewise, female sex 
and taking other hepatotoxic drugs were not associated with increased odds of DILI. Age over 50 
years old, HIV infection, HCV infection, and having both PTB and EPTB (when compared to PTB only) 
were shown to independently increase the odds of having TB DILI. After adjusting for age, sex, HIV, 
use of hepatotoxic drugs and TB site, there was some evidence that HCV modified the effect of DM 
on DILI, although this interaction analysis should be treated with caution. Considering the study 
objectives, the research questions have been answered.   
 
5.1 Exposure variables 
5.1.1 DM 
    From the vast body of studies on risk factors for TB DILI, only a few studies have included DM as 
a comorbidity, having found no association with DILI (130, 275, 280), a finding in agreement with 
the present study. Those studies were not designed to study DM as the main exposure variable of 
interest, such as the present one. 
     In the present study, the multivariate analysis has not found any evidence that DM is associated 
with increased odds of DILI. However, it was found some evidence of an interaction between HCV 





between HCV and DM on the odds of development of DILI, though this did not achieve statistical 
significance. The biological plausibility for this may lie, amongst other reasons, with the potential 
for HCV to exacerbate the hepatotoxicity of DM-associated NAFLD and augment susceptibility to 
DILI. This is consistent with evidence found in the literature on how DM and HCV infection are 
related (218-222). Individuals with DM and HCV concomitantly have worse outcomes (222, 334), 
which might explain an increase in the magnitude of liver damage reflected by an association with 
DILI. No patients with DM were defaulters from treatment, neither cases nor controls.  
 
5.1.2  Age 
    The risk of DILI induced by TB treatment increases with age and the highest incidence occurs in 
individuals above 50 year (153). Other studies are in line with these findings, indicating a possible 
role played by increasing age (130, 136-138, 148, 153, 154, 164, 284, 285, 298, 306, 333, 335-340). 
Bright-Thomas et al. (290) identified a significant trend in increasing age as a risk factor for DILI, with 
risk increasing 16% for every ten-year increase in age (adjusted OR 1.16; 95% CI 1.02 – 1.32; P = 
0.02). The morbidity and mortality of DILI have also been reported to be higher in those patients 
above 50 years of age (341). Gaude et al. (280) have demonstrated that patients over 60 years old 
were independently associated with increased odds of DILI (OR 3.1; 95% CI 1.6 – 7.6; P = 0.002). 
Likewise, Shaberg et al. (130) have found that age 60 years and above was an independent risk factor 
for TB DILI (OR 3.5; 95% CI 1.3 – 10.1; P = 0.02). Warmelink et al. (301) also reported that age over 
60 years was an independent risk factor for TB DILI (OR 18.5; 95% CI 2.3 – 151). 
    Across the literature, however, increasing age has not been reported consistently as a risk factor 
for DILI. In several studies, this association has not been demonstrated (297, 342-344) , while others 
have suggested otherwise and that increasing age is associated with DILI (124, 130, 136, 138, 148, 
152, 153, 281-283, 339, 345, 346). One study reported a TB DILI rate range from 2% to 8% as patients 
grew older (282). Other studies have reported a range from 22% to 33% in patients older than 35 
years of age, compared to a smaller prevalence range of 8% to 17% in those younger than 35 years 
old (152, 281).   
    Not all evidence is supportive of an association with increasing age. One explanation for that could 
be that age was not adjusted for all potential confounders. The higher prevalence of DILI in older 





respective treatments with hepatotoxic agents and these confounders should be considered in the 
analysis. Frequently prescribed drugs in the elderly population include captopril, enalapril, 
clopidogrel, simvastatin, allopurinol, metformin and glibenclamide, all present in category A (50 
published hepatotoxicity cases and above) and category B (between 49 and 12 hepatotoxic cases) 
lists,  in a critical assessment by Björnsson and Hoofnagle (271). Additionally, increased susceptibility 
for hepatotoxicity with old age could be partly due to physiological changes. Intravascular, organ, 
muscle and distribution volumes are smaller in the elderly (347), which might result in impaired 
hepatic drug metabolism and elimination, particularly of drugs metabolized by the cytochrome 
enzyme system (348, 349). Besides, reduced food intake by elderly individuals may cause lower 
availability of nutrients for liver detoxification of TB drugs (350).  Due to the global aging trend (351), 
hepatotoxicity may become an even more serious problem in the near future. 
    Further evidence for the association between older age and DILI comes from the Spanish DILI 
Registry and Latin DILI Registry, which have reported a mean age of 51 and 54 years, respectively, 
in 1,067 well-vetted DILI cases (122). In another study on the outcome and prognostic markers of 
severe DILI (352), non-survivors with DILI were significantly older than those who were able to 
recover and age was found to be an independent predictor of death or transplantation. 
    This study has been able to show that as patients grew older, the odds of DILI increased and were 
the greatest in the older age group, with patients ranging from 71 to 93 years old (OR 12.91; 95% CI 
5.81 – 28.66). However, TB DILI is known to occur also in early childhood. In a retrospective study 
conducted in Japan (353), severe TB DILI was diagnosed in 8% paediatric patients and it was 
associated with being under 5 years old. Other studies have found a similar association between TB 
DILI and children (354, 355).       
 
5.1.3  Sex     
    The female sex was not associated with increased odds of DILI in the present study. This finding 
contrasts with data from other studies reporting an increased risk of DILI in women (136, 138, 148, 
283). Ambreen et al. (311) have observed that the female sex was at a higher risk for DILI. A study 
conducted in India by Gaude et al. (280) has found that female sex was an independent risk factor 
for the development of DILI. Likewise, other studies have shown similar findings (95, 106, 137, 138, 





than for men for DILI requiring a change of TB regimen.   
     Nonetheless, such results have been inconsistent. In accordance with the present study, others 
have shown no increased risk in women (124, 130, 143). One possible reason for that could be 
insufficient numbers leading to unstable estimates. A study conducted in Canada by Yee et al. (137) 
has shown that the female sex was associated with any major side effects from first-line drugs 
(adjusted HR 2.5; 95% CI 1.3 – 4.7), but not with DILI.  A study conducted by Shu et al. (284) reported 
that the risk of DILI was highest in females aged above 67.5 years, followed by males aged above 
67.5 years and females aged 67.5 years and under; the lowest risk was in males aged 67.5 years and 
under. That finding might explain why some studies have not been able to show an association 
between sex and DILI, as the association in some studies, such as that one, was most evident in older 
patients.  
    Studies conducted on patients who had DILI while treating LTBI with isoniazid monotherapy, have 
found no clear evidence of a sex-related difference, either (140, 142, 143). Nonetheless, some 
studies on DILI caused by isoniazid have reported that females are more at risk of developing 
isoniazid-induced DILI than males (276, 294, 295). The underlying mechanisms are unclear and have 
yet to be unravelled, but the female vulnerability might be due to pharmacokinetics and slow 
acetylation enzymatic pattern (356).  Specific incidence rates across the literature, which were 
similar in both sexes until age 49, became more than twice as high in women as in men after this 
age (356). Other factors that might explain a role of female sex in DILI, apart from differences in 
pharmacokinetics, are hormones. It has been suggested that they might change drug metabolism in 
the liver and explain the difference in reporting rates between men and women (357).   
Pyrazinamide is regarded as the most hepatotoxic agent in RHZE and there are three DILI-causing 
drugs in this regimen, so perhaps the apparent discordance between TB treatment DILI and 
isoniazid-related DILI is to be expected. Even so, some TB DILI studies were not able to find any 
association with sex.   
    There is not a universally consistent finding and therefore no consensus view on the impact of sex 
for DILI risk. The contradictory findings in the literature may be due to the diversity of study 
populations and, most importantly, to the impossibility of studies to adjust for all the biological 
covariates acting as confounders.   





5.1.4   Hazardous drinking 
    Several studies, in agreement to this one, have indicated that alcohol drinking is a significant risk 
factor for TB DILI (81, 92, 124, 127, 130, 137, 143, 147, 148, 152-154, 164, 280, 282, 299, 306, 307, 
312, 314-316, 318-320). A surveillance study conducted in the United States in 1979 reported that 
alcohol use has more than doubled the rate of isoniazid-related DILI, with daily intake increasing it 
more than four times (143). A retrospective study conducted in the United Kingdom (342) reported 
any amount of alcohol intake to be an independently important risk factor for DILI (OR 5.94; 95% CI 
2.34 – 15.1). There was a low occurrence of alcohol abuse in that study. Pande et al. (153) also found 
high alcohol consumption to be a significant risk factor for DILI (OR 4.76; 95% CI 2.25 – 10.05). 
     These results have been disputed by other studies (130, 148, 296, 301, 330, 358), possibly 
depending on differences in drinking patterns and study methodologies. The degree of underlying 
alcoholic liver disease has not always been clearly defined in several studies, as was the case in the 
present study, in which alcohol consumption was self-reported, adding to the uncertainty of 
classification of the severity of alcoholic liver damage. Physicians tended to classify drinking patterns 
into three main categories, namely non-drinkers, social drinkers and alcohol abusers, so that there 
was a lack of objectivity and refinement on these data. It was expected that both abusers and social 
drinkers might be misclassified as hazardous drinkers. However, non-drinkers were most likely not 
misclassified as hazardous drinkers and nor were hazardous drinkers misclassified as non-drinkers. 
This covariate was not included in the final model because, in this study, it was not a confounder for 
the effect of DM on DILI (DM M-H OR 1.02; 95% CI 0.57 – 1.81) (Table 6).   
 
5.1.5   HIV infection  
    The present finding of HIV infection as being independently associated with DILI (OR 3.59; 95% CI  
2.25 – 5.73) is in agreement with the literature (88, 90, 92, 156, 164, 306-311). A five-year 
retrospective study in Taiwan (284) reported HIV infection as an independent risk factor for DILI 
during treatment with RHZE (HR 3.08; 95% CI 1.4 – 6.78), but not HCV and HBV. It has been 
suggested that the concomitant use of certain antiretroviral therapy (ART) such as protease 
inhibitors might, at least partially, explain this tendency (359) in the absence of controlling for ART. 





DILI in HIV infected patients (OR 4.4; 95% CI 1.06 – 18.3) (342).  
    According to the ATS Statement (95), HIV positive patients do not seem to present a stronger 
association to isoniazid-related DILI when compared to HIV negative patients (360), although no 
studies showing direct comparisons have been found. Ungo et al. (92) reported that 27% of the HIV 
positive patients developed DILI with TB treatment, compared to 12% of those who were HIV 
negative. All patients had normal baseline liver transaminases, and the HIV positive group 
independently increased 4-fold the risk of having a transaminase level to 120 IU/L. However, the 
potential for hepatotoxicity of ART drugs was not taken into consideration in the analysis. The effect 
of HIV on DILI is considered to be a matter of utmost importance and the widespread use of ART 
should always be taken into consideration in order to correctly assess the mechanisms behind this 
increased risk.   
    The introduction of ART has reduced significantly opportunistic infections among the HIV 
population by between 60% and 90% (361); nonetheless, these drugs may play a role in the 
increased risk of DILI. Efavirenz is on the category A list (above 50 published cases) by Björnsson and 
Hoofnagle (271). A comparison between a group taking ART and/or trimethoprim- sulfamethoxazole 
against a second group taking other classes of hepatotoxic drugs and a third one taking no drugs at 
all, was not performed. Nevertheless, it is noteworthy that most of the HIV positive patients among 
the controls (67.4%; 93/138) and cases (64.1%; 50/78) were taking regularly ART and/or 
trimethoprim-sulfamethoxazole concomitantly with RHZE. When comparing those HIV positive 
patients to those who were taking other hepatotoxic drugs or none, there was no difference 
between the cases and control groups (P = 0.6).      
    An association between low T CD4 lymphocyte counts and DILI has been reported by some studies 
which, having found no evidence of an association between DILI and opportunistic infections and 
their medications, suggested that there might be an unknown immunological factor accountable for 
that (81, 343, 362). A Brazilian study (343) on the relationship between DILI and HIV positive patients 
showed that a T CD4 lymphocyte count < 200 cells/mm3 increased the risk of DILI when compared 
to those with ≥ 200 cells/ mm3  (OR 1.2; P < 0.001). Some studies, however, have found no 







5.1.6   HCV infection 
    The reported HCV prevalence in European countries lies between 0.5% and 2% and high burden 
areas include Africa (particularly Egypt) and Asia (128). In Latin America, specifically in Argentina, 
Brazil, Mexico, Puerto Rico, Peru and Venezuela, the HCV prevalence ranges from 1.4% to 2.5% 
(363). In Brazil alone, there are different estimates of prevalence across its five political regions. The 
Southeast and South regions, being the most densely populated and urbanized in the country, 
present the highest incident rates. In 2016, the prevalence of hepatitis C in Brazil was estimated to 
be 0.7% among those between 15 and 69 years of age and the co-infection HIV-HCV was believed 
to be 9.8% (364). In Porto Alegre, from 2013 to 2017, the incidence of hepatitis C  ranged from 43 
to 102 per 100,000 population (213). Among all Brazilian regions, the South is the one with the 
highest co-infection prevalence, 13.2% of HCV patients are HIV-infected (364). 
    Although results are not universal, a number of studies suggest that co-existing viral hepatitis may 
be an important risk factor for DILI (88-93). The literature suggests that the relative risk of 
developing DILI is fivefold for HCV positive patients; fourfold for HIV positive individuals and 14-fold 
for those co-infected (92). A study by Warmelink et al. (301) reported that chronic HCV infection 
was a significant risk factor for DILI leading to interruption of TB treatment (OR 19.6; 95% CI 2.4 – 
164). In a Brazilian study (343) with HIV-TB co-infected patients, with chronic hepatitis B or C, the 
risk of DILI was significantly increased (OR 18.19; P = 0.03). Ungo et al. (92) has assessed the effect 
of HCV infected patients on DILI and found that approximately 30% of HCV-infected patients 
presented DILI in contrast to 11% among those not HCV-infected. Other studies have suggested that 
HCV is associated with an increased risk of DILI (88, 90, 92, 154, 301, 307-310, 312, 313). Contrary 
to that, other researchers found no evidence of such association (284, 342) and two studies on risk 
factors for isoniazid-related DILI have not shown any increased risk associated with HCV infected 
individuals (312, 365). A possible reason for that could be that by excluding patients with abnormal 
baseline liver transaminases, patients with chronic viral hepatitis were excluded as well, as a result.  
    The prevalence of HCV infection in individuals with DM in a general practice clinic in Brazil has 
been reported as being 3.3% (366), while the national prevalence has been reported by another 
study as being 1.4% (367). Since the 1990’s, studies have demonstrated a higher prevalence of 
hepatitis C in patients with DM when compared to those without DM (368-371). A study in France 
found a prevalence of HCV in patients with DM, when compared to those without DM, of 3.1% vs. 





    The effect of HCV on DILI as well as on DM, in the present study, may have been underestimated, 
given that HCV status was unknown in 30.2% of cases.  
 
5.1.7   HBV infection 
    In this study, there was an unavoidable sparsity of data on HBV infection, as became evident from 
Table 5. On univariate analysis, there was an extremely higher odds of DILI in the HBV infected 
patients. When compared to controls, HBV infected patients were found to be 10 times (OR 10.39; 
95% CI 1.97 - 54.83) as likely to develop DILI than those not HBV infected. However, it must be noted 
that the very small number of individuals with HBV caused the 95% CI to be extremely wide. HBV 
infection was not analysed in terms of a confounding effect for DM on DILI, so it was kept out of the 
multivariate analysis. 
    Several studies have found HBV infection to be a risk factor for DILI (88, 90, 92, 147, 154, 285, 300, 
307-310, 340). In a study by Wong et al. (147), it has been reported that 16% of HBV infected 
patients had symptomatic DILI when compared to 4.7% in those not HBV infected. Also, those 
individuals who were HBV infected developed more severe DILI than those not infected (4.7% vs. 
2.5%). A retrospective case-control study from Korea (90) found a trend towards transaminases 
increase of at least five times the ULN more frequently in the HBV chronically infected patients than 
among those not infected (8% vs. 2%; P = 0.05). However, other studies have found no evidence of 
an association between DILI and HBV (284, 301, 342). At a central London teaching hospital, 2.6% 
of patients with active TB were HBsAg positive but there was no association between DILI and HBV 
(128). Similarly, in a study by Hwang et al. (282), 29% of HBV infected patients treated with RHZE 
had DILI, similar to the 26% found in HBV not infected patients (P > 0.05).  
    Additional investigation is needed, but the severity of liver injury appeared to have been increased 
in those HBV infected patients in a few studies (90, 147, 300). Although there are studies which have 
not stratified patients according to the evidence of a possible acute virus B hepatitis, still the current 
evidence is in favour of HBV chronic infection being associated with DILI.  As concerns isoniazid-
related DILI among those HBV infected, few studies have addressed this issue. In a small study by 
McGlynn et al. (373), no association was found between DILI and HBV. Another study (88) stratified 
HBV infected patients into HBeAg positive and negative patients. Three of 21 patients with HBeAg 





risk. Acute viral hepatitis should always be considered as a differential diagnosis for TB DILI in studies 
conducted in countries where the carrier state of hepatitis B prevalence is high (300, 374). In a study 
conducted in Spain (154), of the patients without risk factors for chronic infection with such viruses, 
only 1% had HCV antibodies and 0.3% had chronic HBV.   
    In a study conducted in Brazil, the prevalence of previous HBV infection with spontaneous cure in 
patients with DM was 16.8% (366). No case of HBsAg positive was found. The study concluded that 
the prevalence of exposure to HBV (16.8%) was greater than the national prevalence of 11.6% in 
the general population aged 20 to 69 years old (366). In Porto Alegre, from 2013 to 2017, the 
incident cases of hepatitis B ranged from 16.3 to 19.2 per 100,000 population (213).  
 
5.1.8   Concomitant hepatotoxic drugs 
    A Brazilian study (343) with TB-HIV co-infected patients has reported an absence of effect of 
hepatotoxic drugs on DILI due to the fact that 100% of cases and 94% of controls were taking 
concomitant hepatotoxic drugs. This finding was in accord with other studies (137, 310, 375), 
including the present one. Additionally, other studies have found no association between 
hepatotoxic drugs and TB DILI (125, 164, 275, 280, 306, 320, 322, 376, 377).   
    Nonetheless, other studies have found alternative results. There have been reports of isoniazid-
related hepatotoxicity during concomitant use of other hepatotoxic drugs such as acetaminophen 
(321-323, 378), methotrexate (324), sulfasalazine (324) and carbamazepine (325, 326). It is 
important to make a clear distinction between idiosyncratic DILI (caused by the administration of a 
drug) and that caused by overdose, such as it happens with acetaminophen. It is a dose-dependent 
acetaminophen-induced toxicity termed intrinsic DILI, and it is predictable, reproducible and much 
insight has been gained into the underlying mechanisms (379-381). Acetaminophen has also been 
reported to be an agent that potentiates alcohol-induced hepatotoxicity (382).  
    A French population-based study conducted by Sgro et al. (96) found the main drugs implicated 
in DILI cases to be antimicrobials, psychotropic, hypolipidemic and non-steroidal anti-inflammatory 
drugs. Another study conducted with 1,038 adult TB patients in a TB clinic in Porto Alegre, between 
1989 and 1994 (383), found that anticonvulsants were independently associated with DILI, with an 





phenobarbital, hydantoin or carbamazepine (OR 25.2; P < 0.0001). 
    Acetaminophen was excluded from the present study analysis because it causes a predictable and 
dose-dependent type of liver injury. Additionally, it is not present in the drugs lists by Björnsson and 
Hoofnagle (271), used by the researchers as a validated source of drug reports. In this study, only 
15 patients, all controls, took acetaminophen as a single drug, and there was no evidence that it had 
been taken in an overdose. Besides, it is a drug that can be bought without a medical prescription 
so the fact that it was not prescribed does not mean that it could not have been taken by patients, 
as opposed to other groups of DILI-causing drugs such as anti-epileptics and antimicrobials, for 
which a medical prescription is required. Considering the retrospective nature of the present study, 
it is fair to assume that any drugs could have been taken without the patient informing them or the 
TB physician registering them on the medical files.  With regard to the use of illegal drugs, the 
present study did not collect data on them.  Although marijuana, crack, cocaine and solvents are 
risk factors for DILI, a study conducted in Brazil has found no evidence of that (343).  
         
5.1.9   Other liver diseases  
    Concomitant other liver diseases are shown in Table 3 and included mostly cirrhosis and liver TB, 
or its presumptive diagnosis. Cirrhotic patients were not analysed in terms of their different 
aetiologies, but were most probably either of an alcoholic nature or HCV related, among others. This 
variable was not included in the multivariate analysis for two reasons: first, because it was not a 
confounder for the effect of the main exposure, DM, on DILI (Table 6); and second, it was much 
associated with other variables: hazardous drinking, HCV, HBV and TB site, in so far as liver TB was 
a frequent finding among EPTB sites (Table 4).  
    Of the 22 cases who presented a chronic liver disease, 50% (11/22) were cirrhotic, while there 
were no cirrhotic individuals among the controls. Only one cirrhotic patient was known to be HBV 
positive, but he was a hazardous drinker as well. Of the seven patients with hepatitis C infection, 
four (57.1%) were hazardous drinkers. Finally, among the eight patients who were cirrhotic and 
known to be hazardous drinkers, (who were very likely also alcohol abusers), four (50%) had 
hepatitis C chronic infection as well. These data on the group of cirrhotic patients with DILI help 
make clear the difficulties regarding the other liver diseases variable, which was devised originally 





anticipated to be fairly prevalent, as well as other granulomatous hepatitis and steatosis. As 
diagnostics methods for steatosis were not expected to be routinely performed in TB clinics, for 
instance, the covariate other liver diseases most probably underestimated the effect of chronic liver 
diseases on DILI. Because of the intimate association with alcohol drinking, HCV and HBV, the 
multicollinearity between these exposure variables precluded its being added to the multivariate 
analysis.    
         
5.1.10   TB site  
    The extent of TB disease has been studied and reported as a risk factor for the development of 
DILI, but mostly in terms of the radiological aspect and extent of pulmonary disease (153, 280). For 
instance, in one study, the disease was considered to be extensive if it involved the equivalent of 
more than one lung radiologically and presented multiple cavities (153). In this study, extensive 
pulmonary disease was found to be a risk factor for DILI (OR 4.5; 95% CI 1.88 – 10.93). However, in 
the same study, the presence of miliary shadows on chest radiographs were not associated with any 
increased risk for DILI. Gaude et al. (280) reported extensive pulmonary disease as an independent 
risk factor for the development of TB DILI (OR 2.3; 95% CI 2.1 – 4.9). Another study (284) used 
radiological scores to examine TB extent on chest radiographs (384), thus considering radiological 
lesions only, but did not find TB extent to be associated with an increased risk of DILI.  
    Several other studies have shown an increased risk of DILI associated with more extensive TB 
disease (148, 150, 153, 155, 297, 309, 330, 331).  One study conducted by Warmelink et al. (301) 
classified TB morbidity according to WHO criteria (385), which differentiates between pulmonary 
and extrapulmonary TB and further stratifies the latter category into least and most severe. They 
found no association between TB morbidity and hepatotoxicity (P = 0.3), in contrast to other studies 
(124, 148, 153, 155). A study on DILI among patients co-infected with HIV classified the disease into 
pulmonary and extra-pulmonary forms but also considered disseminated disease through 
bloodstream involving sites such as the bone marrow, liver or at least two or more noncontiguous 
sites (343). They found no evidence of increased odds of DILI associated with TB morbidity in that 
population (P = 0.4). Another study (316) found some evidence of an association between EPTB 
(abdominal TB) and DILI (P = 0.05) when compared to pulmonary TB and other forms of EPTB.  A 





than PTB patients. Contrary to that, other studies could not find any association between DILI and 
extensive pulmonary disease (313, 335). A prospective cohort study conducted in Ethiopia (386)  
reported no association between DILI and EPTB.   
    As can be surmised, studies differ in terms of their definitions for the extent and severity of TB 
disease, but there seems to be a trend for finding more advanced disease as a predictor for DILI. A 
study conducted at the Hospital Sanatório Partenon in Porto Alegre, where 676 TB patients were 
followed between 1990-99, has found that miliary TB was a risk factor for DILI (OR 2.3; P = 0.03) 
(129).  
    The concept of extensive disease was sought to be taken further and it was hypothesized that 
having TB disease limited to the lungs could be considered, in general terms, less extensive than 
having both PTB and EPTB. This covariate, TB site, is a categorical non-ordered variable. An EPTB 
site, such as pleura or lymph node alone would present a much less extensive and milder disease 
than a bilateral and cavitary PTB, for instance. It was beyond the scope of this study the exact 
classification and characterization of the level of TB extent and miliary dissemination, however 
interesting it would have been to examine the relation between DILI and increasing degrees of TB 
disease severity extent.           
    As for EPTB, it is worth noting that granulomata are nonspecific findings. Granulomatous hepatitis 
may indicate an infectious, inflammatory or neoplastic aetiology (95) and it is one of the conditions 
causing DILI. Granulomatous hepatitis with increased transaminases presents itself in the case of 
hepatic TB and may present with abnormal baseline transaminases which improve with adequate 
TB treatment. In this study, there were not known baseline transaminases for most of the patients, 
except for those that came to the TB clinics after being discharged from hospital. It is reasonable to 
assume that patients with elevated transaminases and TB disease in other extrapulmonary sites 
would have been believed to present with subclinical liver TB, presumably, if abdominal scans 
showed a certain degree of liver abnormalities. Having both PTB and EPTB acted as a surrogate for 
more extensive TB.  






5.2   Time to DILI  
     It is well known that hepatotoxicity occurs, as a rule, within weeks to months (387), so that DILI 
can be detected prematurely and mitigated. In the literature, it has been found that in most 
patients, TB DILI has started within 15 days after the start of treatment (275, 316, 343, 345, 388). 
Several other studies have reported similar findings (155, 272, 301, 331, 389). Median time to onset 
of DILI has been reported as 12.5 days (IQR  7 - 30); more than half of DILI cases (53%) occurred 
within the first 14 days, 72% within the first 28 days and 87.6% occurred by 56 days (342). These 
findings have been comparable to others (34, 91, 124, 126, 138, 155, 275, 345). There have been 
reports with slightly longer onset times (138, 284, 390). For instance, Sharma et al. (391) found a 
median time to DILI of 23 days (IQR 14 – 44 days) and Nader et al. reported that 89.4% of patients 
developed DILI within the first 30 days of RHZ (91). Tuberculosis drug-related DILI often developed 
one to three months after DILI in a study by Chen et al. (340) and also by Kim et al. (289). The present 
results mirror those found by other researchers. It was found that the time elapsed to DILI in 152 
cases had a median of 17 days (IQR 9 – 49 days). 
    The accurate assessment of the time to DILI is more complex and beyond the possibilities of this 
study.  The onset of injury may be defined as either the date of the onset of symptoms, or signs such 
as jaundice or bilirubinuria; or the first abnormal laboratory tests results. As for symptoms and 
clinical signs, in many instances the exact date was not available on the hospital medical discharge 
notes, as opposed to clinic records, which frequently have these data more accurately registered. It 
is worth of note that hospitalized patients are more likely to have their DILI diagnoses earlier than 
ambulatory patients because, in hospital, laboratory tests are routinely done daily, regardless of 
symptoms. Also, the first date of abnormal transaminases does not necessarily reflect the first day 
of injury. Based on these reflections, there may have occurred some misclassification concerning 
the exact date of DILI, which was deemed to be later than it really was, in some instances, although 
the proportion of patients whose DILI was diagnosed in hospital and therefore having a more 
accurate DILI date, was 7.6% (12/157). In the present study, time to DILI was not affected by DM 
status (Figure 1).   
    According to Picon et al. (383), after the discontinuation of TB treatment, the liver injury 
decreases in an average of 18 days (8 - 39 days). It has been suggested that regular monitoring of 





and this monitoring has been recommended for other DILI-causing drugs, apart from rifampicin, 
isoniazid and pyrazinamide, like disease-modifying anti-rheumatic drugs, for instance (392).  
 
5.3   Confounding  
    Being the main exposure of interest, DM had its effect on DILI stratified by the other covariates 
(Table 6). The crude OR 1.10 (95% CI 0.62 – 1.94) was compared to the adjusted Mantel-Haenszel 
DM OR. The covariates age, HIV infection, hepatotoxic drugs and TB site acted as confounders in the 
effect of DM on DILI. Hepatitis C infection acted as effect modifier.  
 
5.3.1   Age 
    Older age is a well-known risk factor for DILI. In the present study, age proved to be a strong 
confounder, as the effect of DM on DILI diminished from OR 1.10 (0.62 – 1.94) to OR 0.72 (95% CI 
0.40 – 1.31) (Table 6). Older age is associated both with DILI and with DM, so was expected to be a 
strong confounder. 
 
5.3.2   HIV 
    Among both cases and controls, most of the patients with DM were not HIV positive. The HIV 
infection was confounding the effect of DM on DILI, which became higher once DM was adjusted 
for HIV (M-H OR 1.44; 95% CI 0.80 – 2.60) (Table 6). In the multivariate analysis (Table 7), HIV had a 
strong effect on DILI (OR 3.59; 95% CI 2.25 – 5.73), while DM had no evidence of having any effect 
(OR 0.88; 95% CI 0.45 – 1.71). HIV was not initially expected to be a confounder, as it is not 
associated with DM.  
 
5.3.3   Hazardous drinking  
    Among the controls, hazardous and not hazardous drinkers had nearly the same DM prevalence 





in the hazardous drinking group, so that patients with DM were more hazardous drinkers than not. 
A little of the effect on DILI caused by DM may have been attributable to alcohol drinking, although 
it did not act as a confounder for the effect of DM on DILI. The DM OR decreased from OR 1.10 (95% 
CI 0.62 – 1.94) to OR 1.02 (95% CI 0.57 – 1.81). Nevertheless, the literature presents some  evidence 
that DM is associated with alcohol drinking (196, 198, 204). 
 
5.3.4   Hepatotoxic drugs 
    Among the controls, most patients with DM were taking hepatotoxic drugs, whereas among the 
cases, the prevalence of patients with DM taking hepatotoxic drugs was the same as those not taking 
them, so that for those with DM and DILI, it made no difference whether they were taking additional 
hepatotoxic drugs or not. There was a suggestion that hepatotoxic drugs might be acting as effect 
modifier on the effect of DM on DILI (P-value for the Test of Homogeneity of ORs = 0.01) (Table 6), 
but the interaction was not confirmed by the multivariate analysis (P-value for the interaction = 0.1) 
(Tables 7 and 8).       
 
5.3.5   TB site 
    Among the controls, patients with DM had a higher prevalence of only PTB, followed by only EPTB 
and, least of them, both PTB and EPTB. Patients with DM are often immunosuppressed, so it would 
be reasonable to hypothesize a higher prevalence of more extensive TB disease in this group. 
However, this was not so. Among the cases, most of individuals with DM had only PTB (88.2%), and 
none had only EPTB. This may have contributed to the impossibility to find an association between 
DM and DILI, even though it was possible to find increased odds of DILI in patients with more 
extensive disease (PTB and EPTB). Patients with DM presented the same tendency for having a 
higher prevalence of PTB than EPTB, as is the case in the general population. The confounding effect 
of TB site on the effect of DM on the odds of having DILI should be interpreted with caution.   
 
5.4   Effect modification  





6). Among the controls, patients with and without DM had similar HCV prevalence, but among the 
cases, the HCV prevalence in the DM group was nearly four times higher than in those without HCV 
(25% vs. 6.61%). When patients with DM were stratified by HCV status, the OR for the effect of DM 
on DILI increased from OR 1.10 (95% CI 0.62 – 1.94) to an OR 2.67 (95% CI 0.72 – 9.93; P = 0.1) in 
the HCV stratum and decreased to an OR 0.65 (95% CI 0.30 – 1.39; P = 0.3) in the non-HCV stratum 
(data not shown). The Test of Homogeneity of ORs P-value (P = 0.06) suggested that there might be 
an interaction between HCV and DM (Table 6). In the multivariate analysis (Table 9), after adjusting 
for age, sex, HIV, hepatotoxic drugs and TB site, there was some evidence that having HCV would 
affect the effect of DM on DILI, when compared to those without DM (P-value for the interaction = 
0.02). Having DM was associated with a more than three-fold increase in odds of DILI among those 
with HCV (OR 3.37; 95% CI 0.86 - 13.16; P = 0.08), whereas DM was associated with a 46% reduction 
in odds of DILI among those without HCV (OR 0.54; 95% CI 0.23 - 1.26; P = 0.2). The large P-values 
for the strata reflect the stratification and small number of individuals. It is worth noting that there 
is evidence in the literature that not only DM worsens HCV outcomes but that this association leads 
to worse outcomes for DM as well (222, 334). Although those results should be treated with caution, 
there is a body of evidence that agrees with the finding of an effect modification in those patients 
with DM and concomitant HCV, as opposed to those with DM without it, regarding their odds of 
presenting with TB DILI. The double burden of these two diseases is likely to increase the odds of 
DILI in a group of patients with the additional burden of a chronic consumptive infection and a 
prolonged intake of three hepatotoxic drugs.       
 
5.5   Limitations of this study inherent to case control studies  
5.5.1   Information bias 
    Being a retrospective study, data reported on certain covariates such as hazardous drinking, use 
of concomitant hepatotoxic drugs and concomitant liver diseases were subject to inaccuracies and 
subjectivity.  Data on blood tests were subject to physicians’ discretion and individual working 
routines, so not consistently available on medical documentation.  The literature has reported a few 
risk factors for TB DILI which have not been analysed in the present study and which might have, 
possibly, played a role as confounders. It was not feasible to comment on data that were not a part 





    Genetic factors have been found to have an effect on DILI (124, 152, 153, 393) and were not 
analysed in this study. Several genetic polymorphisms in drug metabolizing enzymes have been 
associated with DILI (164, 294, 316, 390) such as slow acetylator status (N-acetyl-transferase 2) (153).  
However, it has been observed that both fast and slow acetylators are prone to develop DILI with 
RHZE (138, 149). When acetylation has been studied by phenotypic assays, slow acetylators have 
presented more DILI in some studies (282, 299, 355, 394), although not in others (395, 396). A slow 
acetylator phenotype has been associated with an increased risk of isoniazid-related DILI (OR 4.25; 
95% CI 1.36 – 13.22; P = 0.01) (332) and another study has found that slow acetylators developed 
more TB DILI (26% vs. 11%), and more severe, than fast acetylators (152).  
    Malnutrition, ascertained either by body mass index or serum albumin, is another widely accepted 
risk factor for TB DILI (124, 153-155, 164, 280, 282, 295, 297, 327-329) that was not captured by this 
study. One mechanism for the effect of undernutrition on DILI is the depletion of glutathione stores 
that renders individuals vulnerable to oxidative injuries (316). A study in India (397) has found a 3-
fold higher incidence of TB DILI in undernourished patients. Although weighing patients monthly 
during medical appointments is a routine procedure at the TB clinics, height measurements are not, 
and nor are serum albumin tests.   
    The present study has not addressed the issue of recreational drug use because this type of data, 
when asked retrospectively, is likely to be quite unreliable, considering the substantial number of 
socially vulnerable individuals with TB. Drug misuse has been studied as a risk factor for DILI, but is 
not a well-established one (301). 
    Data on drugs were captured based on prescriptions registered on medical records from the 
clinics and hospital discharge documentation. As such, they may have been both overestimated, 
because the patient might not have taken the medication prescribed; as well as underestimated, 
because the patient might have taken other hepatotoxic drugs without the physician’s awareness 
or consent. Hospital discharge documentation, however thoroughly informative, might not have all 
the drugs prescribed in them, nor did all patients bring their hospital notes to TB clinic appointments.    
    Alcohol consumption was self-informed by patients and any daily alcohol intake was likely to be 
either underestimated or under-reported by them. Likewise, data on alcohol intake was not 
reported by physicians in a standardized way; for instance, as in the number of alcohol units taken 
daily or over the weekend. Rather, the physicians reported that a patient was either “alcoholic”, 





dependence from hazardous drinking, some hazardous drinkers must have been misclassified as 
alcoholics by their physicians and vice versa. In practical terms, they were at least hazardous drinkers, 
so this limitation was of no importance to the final analysis. Still, there is a possibility that the 
prevalence of hazardous drinkers may have been rather underestimated than overestimated. 
Alcohol consumption was self-reported and under-reporting alcohol misuse is a reality.    
    Other important cause of liver injury are herbal products and dietary supplements, which were 
not captured by this study. They are frequently overlooked during anamnesis, and these questions 
may have been neither asked by physicians nor spontaneously informed by patients.  
    A certain degree of misclassification bias is to be expected in retrospective studies. For instance, 
missing results on tests for HCV, HBV or DM. The reason for the DM variable being classified in 
“known DM” and “not known to have DM” has been described previously. There was no 
demonstrable association between known DM and DILI but one cannot exclude the possibility that 
some undiagnosed DM subjects were included in the “not known to have DM” category and, but for 
the lack of a blood test, may have been differently classified.   
 
5.5.2   Selection bias  
    Another type of bias inherent to case control studies is the selection bias (398). The present study 
sought to prevent it by selecting the controls from the same population as the DILI case population. 
They were TB patients of all ages and backgrounds being treated with the same hepatotoxic drug 
combination (RHZE) and consequently as likely to have the same clinical and epidemiological 
characteristics as the cases. It is important to note that although DILI patients were followed-up at 
the CRTB clinics, there was no bias towards TB-HIV co-infected patients, because the DILI diagnoses 
were made also in primary health care clinics, where co-infected patients are not routinely treated, 
and several hospitals.  
 
5.6   Study strengths and weaknesses  
5.6.1   Study strengths 





factor for DILI and to seek to investigate its possible associations with other well-known risk factors. 
Considering the triple burden of DM, TB and DILI, the study hypotheses were fully justified and 
warranted further investigation.    
    The main strengths of this study include the SITETB electronic platform, which enabled us to 
capture the totality of the DILI cases severe enough to have needed a change of drug regimen. 
Another strength of this study was the inclusion of a heterogeneous study population with a wide 
spectrum of risk factors for DILI. This study was not restricted to adults. Serious side effects can 
occur in young children, also, and it has been shown that pyrazinamide is the most common 
offender (353). 
    The small group of TB physicians provided a reasonably standard approach to identification and 
management of a more serious DILI episode requiring a change of treatment and then reporting and 
registering it onto SITETB, which was the source database for DILI cases. Regardless of where the 
patient was being treated when DILI was diagnosed, were it in a hospital or in an outpatient Family 
Medicine clinic, the decision of a change of treatment was endorsed by the same TB physicians in 
the five TB clinics. This aspect should allow for comparability of results and internal validity. The 
primary outcome measure (DILI needing a change of treatment) was based on current guidelines 
for TB DILI management, but as there is not a unique procedure to DILI management, it is actually 
possible that some DILI patients who had their treatment changed, could have been successfully re-
challenged with RHZE.  
 
5.6.2   Study weaknesses 
   There were several important limitations to the study. First, the sample size needed was not 
obtained, which led to a decrease in the study power; second, routine rapid tests for HCV and HBsAg 
were not offered during the whole period of the cases diagnosis; they became systematically 
implemented in the referral TB clinics as of 2015. As a result, data on HBV and HCV status were 
missing for a number of patients; they were not offered by the TB Programme at the clinics and, 
additionally, blood tests are subject to physician discretion. The same was not the case with HIV 
screening tests. The coverage of HIV status in TB patients was nearly total. The prevalence of co-
infection with HBV and HCV among HIV positive patients have been reported in the international 





prevalence of hepatitis C in Brazil was estimated to be 0.7% among those between 15 and 69 years 
of age and the co-infection HIV-HCV was estimated to be 9.8% (364). There might have been a 
number of patients co-infected that was not identified, albeit a small number. Consequently, 
multicollinearity between these three variables could not be excluded.   
    Tuberculosis DILI diagnosis is often based on circumstantial evidence. It includes the temporal 
relationship between the start of RHZE and the onset of liver injury, as well as its resolution after 
drug withdrawal. However, it certainly requires the exclusion of acute viral hepatitis and other 
possible causes. It has been shown that patients with acute viral hepatitis take a longer time for 
normalization of increased liver transaminases. Because the DILI diagnosis is usually prompt and the 
TB patient has easy access to medical consultations, there is frequently an absence of fever and the 
improvement of symptoms follow shortly, those are probably the reasons why some patients did 
not have a viral hepatitis serology panel performed. As far as it could be ascertained, among the 157 
DILI cases in the study, there were no misdiagnoses as to the hepatitis aetiology.  
    Possible confounding and bias could not have been completely excluded. Different backgrounds 
and life styles among patients can create confounding factors impossible to assess. For instance, it 
was not possible to include diverse ethnic groups in the study, although Porto Alegre is a multi-
ethnical capital. The incidence of Muslim population is minimal, so that a bias towards drinking 
habits would have been very unlikely. A few other risk factors for DILI were also not controlled for, 
such as a previous DILI episode and increased pre-treatment transaminases. Baseline altered liver 
tests may signal a liver comorbidity. Nevertheless, no substantial underestimation of the actual 
effect of these risk factors for DILI due to the failure to identify these high-risk individuals occurred, 
because chronic liver diseases were captured and analysed.      
    Baseline transaminase tests were not always available. Patients with altered baseline 
transaminases are not treated with RHZE, they are instead put on one of the hepatotoxicity 
regimens such as capreomycin, levofloxacin and ethambutol (CpLxE) or rifampicin, levofloxacin and 
ethambutol (RLxE) and thus very unlikely to present DILI.  Ascertainment bias could have occurred 
as some alcohol abusers could have actually a mild cirrhosis or NAFLD without the physician being 
aware. Ultrasound or CT scans are not routinely ordered. Besides, patients who were previously 
known to have a history of hazardous drinking, NAFLD or of a previous DILI episode could have been 
more frequently tested for HCV, HBV or transaminases than those who had no such histories.  





screened for DM for confirmation tests were considered as “not known to have” DM. There was no 
demonstrable association between known DM and DILI but there cannot be excluded the possibility 
that some undiagnosed DM subjects were included in the “not known to have DM” classification 
and, but for the lack of a test, may have been differently classified. 
    Likewise, patients who were not tested for HIV, HCV and HBV were considered to be “not known 
to have” HIV, HCV and HBV. Therefore, results could present an underestimation of these exposures, 
with the exception of HIV status, as the TB Programme in Porto Alegre has a systematic HIV 
screening coverage. Rapid tests for HIV were implemented back in 2014, before screening for HCV 
and HBV tests ever started. It is also worth noting that the lack of reporting of critical data such as 
HCV and HBV tests may have been because the laboratory results were normal and, therefore, not 
deemed relevant to be registered.  
    For a number of the variables, the missingness is significantly different between cases and 
controls and usually greater in controls. This is not unexpected because patients with DILI are more 
likely to have more complete questioning and investigations for liver disease.  It is likely that 
missingness was smaller amongst cases in relation to DM, HCV, HBV and other liver diseases because 
they were more likely to be tested and screened for risk factors for DILI than the controls. This same 
pattern of missing data could be explained by the fact that patients with EPTB are likely to be more 
extensively ill than those having only PTB, in general, and therefore were probably more thoroughly 
investigated for risk factors for DILI. However, with hepatotoxic drugs, missing data was higher 
amongst the cases and one explanation for that could be that of all DILI risk factors, drug history 
was the least considered by physicians and inquired during anamnesis, even after DILI had occurred.  
    Multiple imputation could be an alternative approach to account for missing data in the exposure 
and confounders. This approach is usually performed under the assumption that the mechanism 
causing the missing data is “Missing at Random”. Even though this assumption may be plausible, it 
cannot be verified by the data. 
    Lastly, with the sample size achieved, the study had a 70% power to detect a measure of effect 
(OR) of 2.01, which allowed to answer the study questions. Considering a study sample size of 157 
cases and 634 controls and a DM prevalence among the controls of 10%, the study has an 80% 






5.7   Conclusions 
    The association between TB and DM and their synergistic action in causing morbidity and 
mortality has been long recognised. The full extent of this double burden, in particular its 
consequences regarding the care and control of these two diseases, has yet to be fully explored. 
    While the global incidence of DILI is small, its impact in health outcomes is substantial. TB DILI will 
remain a problem that carries both clinical and regulatory significance for as long as new drugs 
continue to enter the market. Physicians must always weigh potential risks vs. benefits. Continual 
efforts in studying determinants of drug induced hepatotoxicity may eventually result in mitigation 
of detrimental factors for TB outcomes.  
    The present study supports the concept that specific groups of patients are at a higher risk for 
developing DILI. A major goal of this study was to determine if DM increases the odds of DILI in 
patients taking RHZE. As far as it has been possible to ascertain, no studies designed to investigate 
the role of DM being a major risk factor for DILI have been conducted in Brazil or elsewhere. 
    This study is limited by its retrospective nature. It was sought to determine whether DM is 
associated with an increased risk of TB DILI and to further investigate any risk factors associated 
with the effect of DM on DILI. No association between DM and increased odds of DILI was found. 
Sex and concomitant hepatotoxic drugs were not associated with increased odds of DILI, either. 
Nevertheless, age over 50 years old, HIV infection, HCV infection, and having both PTB and EPTB 
(when compared to PTB only) were shown to independently increase the odds of having TB DILI and 
these findings corroborate evidence from the literature. Considering the study objectives, the 
research questions have been answered. 
    It was deemed important to investigate the issue of TB DILI in a group of patients characterized 
by an impaired immune system and complex metabolic disorders including hepatic involvement.  As 
far as it could be ascertained, this investigation with a focus on DM is pioneer among research on 
TB DILI and offers data for comparisons with future studies and improvement in the knowledge of 
the subject.  
     
5.8   Recommendations  
    Based on the present study findings, TB patients with DM being treated with the first-line regimen, 





test monitoring. This study recommends that those patients who are older than 50 years of age, HIV 
positive, HCV positive or presenting both PTB and EPTB, be instructed by the TB team about DILI 
symptoms awareness. Indeed, those patients should have their liver tests monitored, as they are at 
increased odds of developing DILI and monitoring has been widely advised in the literature.   
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APPENDIX A   
Tables of notified incident cases and treatment outcomes from 2013 to 2017 in the five 
TB referral clinics of Porto Alegre, Brazil.  
 
Table A1. Number of notified incident TB cases per referral TB clinic per year in Porto Alegre, Brazil 
Number of notified incident TB cases 
TB Clinic 2013 2014 2015 2016 2017 Total 
Clinic 1 93 84 142 123 97 539 
Clinic 2 156 153 136 142 113 700 
Clinic 3 164 127 108 81 82 562 
Clinic 4 127 102 104 67 69 469 
Clinic 5 262 201 145 116 92 816 





Table A2. Frequencies of outcome events per referral TB Clinic in Porto Alegre - 2013 




















69 17 0 4 0 1 1 1 93 
Clinic 
2 
112 30 1 3 5 3 2 0 156 
Clinic 
3 
126 26 2 2 4 1 3 0 164 
Clinic 
4 
61 57 1 4 2 1 0 1 127 
Clinic 
5 
125 96 4 7 5 4 18 3 262 
Total 493 226 8 20 16 10 24 5 802 
 







Table A3. Frequencies of outcome events per referral TB Clinic in Porto Alegre – 2014 
Frequencies of outcome events 















Clinic 1 61 12 2 3 3 3 0 0 84 
Clinic 2 107 29 3 3 4 6 1 0 153 
Clinic 3 91 22 1 4 2 2 5 0 127 
Clinic 4 49 44 2 1 1 2 2 1 102 
Clinic 5 98 51 1 0 7 4 37 2 200 
Total 406 158 9 11 17 17 45 3 666 
 
DRTB: drug resistant tuberculosis; TB: tuberculosis 
 
 
Table A4. Frequencies of outcome events per referral TB Clinic in Porto Alegre - 2015 




















97 23 0 3 4 6 0 9 142 
Clinic 
2 
100 24 0 3 3 1 1 4 136 
Clinic 
3 
75 22 1 3 2 1 2 2 108 
Clinic 
4 
56 36 0 5 3 2 1 1 104 
Clinic 
5 
56 24 1 3 10 1 41 9 145 
Total 384 129 2 17 22 11 45 25 635 
 






Table A5. Frequencies of outcome events per referral TB Clinic in Porto Alegre - 2016                                                         
Frequencies of outcome events 















Clinic 1 82 22 1 1 9 3 1 4 123 
Clinic 2 103 18 3 3 3 2 2 8 142 
Clinic 3 54 15 1 3 1 1 3 3 81 
Clinic 4 43 14 1 2 3 1 3 0 67 
Clinic 5 35 15 1 5 4 4 39 12 116 
Total 317 84 7 14 20 11 48 27 529 
 
DRTB: drug resistant tuberculosis; TB: tuberculosis 
 
 
Table A6. Frequencies of outcome events per referral TB Clinic in Porto Alegre - 2017    




















63 12 1 1 8 4 1 6 1 97 
Clinic 
2 
92 12 2 1 2 1 1 1 1 113 
Clinic 
3 
57 11 1 2 4 2 2 1 2 82 
Clinic 
4 
45 16 2 2 2 0 2 0 0 69 
Clinic 
5 
27 8 0 2 5 1 34 3 12 92 
Total 284 59 6 8 21 8 40 11 16 453 
 








APPENDIX B   
TB diagnosis methods 
 
Table B1. TB diagnosis methods in 791 active TB cases 
Diagnosis methods 
Cases (n = 157) Controls (n = 634) 
Frequency % Frequency % 
Smear 48 30.6 200 31.6 
Culture 53 33.8 162 25.6 
Molecular Biology* 26 16.6 70 11.0 
Not confirmed  30 19.1 202 31.9 
 

















APPENDIX C  
Tables from the paper “Categorization of drugs implicated in causing liver injury: Critical 
assessment based on published case reports” by E. S. Björnsson and J. H. Hoofnagle  
 
Table C1. Category A (≥50 Published Cases) 
Drug Nº Ingredient 
Number of 
Cases 
Fatalities Rechallenge Year Classification 
1 Allopurinol >100 1 1 1965 
Rheumato-
logic 






>100 1 1 1981 Endocrine 













>100 1 1 1968 
Immuno-
modulatory 
7 Busulfan >100 1 0 1954 
Antineo-
plastic 
8 Carbamazepine >100 1 1 1968 CNS 











Drug Nº Ingredient 
Number of 
Cases 
Fatalities Rechallenge Year Classification 
11 Dantrolene 51 1 1 1974 CNS 
12 Diclofenac >100 1 1 1988 Analgesic 
13 Didanosine >100 1 1 1991 
Antimicro-
bial 




15 Efavirenz >100 1 0 1998 
Antimicro-
bial 






>100 0 1 Pre-1980 Endocrine 
18 Floxuridine >100 1 0 1970 
Antineo-
plastic 
19 Flucloxacillin >100 1 1 N 
Antimicro-
bial 
20 Flutamide >100 1 1 1989 
Antineo-
plastic 
21 Halothane >100 1 1 1956 CNS 
22 Hydralazine >100 1 1 1984 
Cardiovas-
cular 





Drug Nº Ingredient 
Number of 
Cases 
Fatalities Rechallenge Year Classification 







56 1 1 1986 
Antimicro-
bial 
26 Interferon-β >100 1 1 1993 
Immuno-
modulatory 
27 Isoniazid >100 1 1 1974 
Antimicro-
bial 
28 Ketoconazole >100 1 1 1981 
Antimicro-
bial 
29 Methotrexate >100 1 0 1971 
Antineo-
plastic 
30 Methyldopa >100 1 1 1962 
Cardiovas-
cular 
31 Minocycline >100 1 1 1971 
Antimicro-
bial 
32 Nevirapine >100 1 1 1996 
Antimicro-
bial 
33 Nimesulide >100 1 1 N Analgesic 











Drug Nº Ingredient 
Number of 
Cases 
Fatalities Rechallenge Year Classification 
36 Propylthiouracil >100 1 1 1948 Endocrine 
37 Pyrazinamide >100 1 1 1971 
Antimicro-
bial 
38 Quinidine 53 1 1 1950 
Cardiovas-
cular 
39 Rifampin >100 1 1 1971 
Antimicro-
bial 





zole with TMP 
>100 1 1 1980 
Antimicro-
bial 
42 Sulfasalazine >100 1 1 1950 
Rheumato-
logic 
43 Sulfonamides * >100 1 1 1973 
Antimicro-
bial 
44 Sulindac >100 1 1 1978 Analgesic 
45 Telithromycin 79 1 0 2004 
Antimicro-
bial 
46 Thioguanine 56 1 0 1966 
Antineo-
plastic 
47 Ticlopidine >100 1 1 1985 
Hematolo-
gic 






* Groups of agents  




























Table C2. Category B (12–49 Cases) 
Drug Nº Ingredient * 
Number of 
Cases 
Fatalities Rechallenge Year Classification 
1 Acarbose 13 1 0 1995 Endocrine 
2 Amitriptyline 18 1 1 1961 CNS 
3 Amodiaquine 37 1 1 1977 
Antimicro-
bial 






12 1 0 1972 
Antineo-
plastic 
6 Azithromycin 30 1 0 1991 
Antimicro-
bial 
7 Captopril 16 1 0 1981 
Cardiovas-
cular 
8 Cefazolin 25 0 0 1973 
Antimicro-
bial 
9 Ceftriaxone 15 1 0 1984 
Antimicro-
bial 




13 0 0 1958 Endocrine 
12 Chlorzoxazone 41 1 0 1958 CNS 







Drug Nº Ingredient * 
Number of 
Cases 
Fatalities Rechallenge Year Classification 
14 Ciprofloxacin 28 1 0 1987 
Antimicro-
bial 
15 Clarithromycin 14 0 1 1991 
Antimicro-
bial 
16 Clindamycin 12 1 0 1970 
Antimicro-
bial 
17 Clopidogrel 14 1 1 1997 
Hematolo-
gic 
18 Cloxacillin 16 0 1 1974 
Antimicro-
bial 





25 1 1 1959 
Antineo-
plastic 
21 Cyproterone 49 1 1 N 
Antineo-
plastic 
22 Dacarbazine 24 1 0 1975 
Antineo-
plastic 
23 Dicloxacillin 20 0 1 1968 
Antimicro-
bial 
24 Doxorubicin 16 1 0 1974 
Antineo-
plastic 





Drug Nº Ingredient * 
Number of 
Cases 
Fatalities Rechallenge Year Classification 
26 Enalapril 25 1 0 1985 
Cardiovas-
cular 
27 Enflurane 29 0 0 1972 CNS 
28 Etanercept 16 1 1 1998 
Immuno-
modulatory 
29 Ethionamide 12 1 1 1965 
Antimicro-
bial 
30 Felbamate 15 1 0 1993 CNS 
31 Fenofibrate 24 0 1 1993 
Cardiovas-
cular 
32 Fluconazole 25 0 0 1990 
Antimicro-
bial 






13 1 0 1964 Endocrine 
35 Haloperidol 25 0 0 1967 CNS 
36 Heparin 42 0 0 Pre-1980 
Hematolo-
gic 
37 Imatinib 39 1 1 2001 
Antineo-
plastic 





Drug Nº Ingredient * 
Number of 
Cases 
Fatalities Rechallenge Year Classification 
39 Irinotecan 31 0 0 1996 
Antineo-
plastic 
40 Isoflurane 25 1 1 1979 CNS 
41 Itraconazole 18 1 1 1992 
Antimicro-
bial 
42 Ketamine 15 0 1 1970 CNS 
43 Lamotrigine 33 1 0 2007 CNS 






40 1 0 1996 
Antimicro-
bial 
46 Lisinopril 14 1 0 1987 
Cardiovas-
cular 
47 Lovastatin 12 0 0 1987 
Cardiovas-
cular 
48 Melphalan 21 1 0 1964 
Antineo-
plastic 




27 0 0 1959 Endocrine 
51 Moxifloxacin 13 1 0 1999 
Antimicro-
bial 





Drug Nº Ingredient * 
Number of 
Cases 
Fatalities Rechallenge Year Classification 
53 Nifedipine 12 0 1 1981 
Cardiovas-
cular 




16 1 1 1989 
Gastroin-
testinal 
56 Oxacillin 36 0 0 1989 
Antimicro-
bial 
57 Oxaliplatin 12 0 0 2002 
Antineo-
plastic 
58 Paroxetine 23 0 0 1992 CNS 
59 Penicillamine 22 1 1 1970 Toxicology 
60 Phenobarbital 30 0 0 1911 CNS 
61 Piroxicam 12 0 0 1982 Analgesic 
62 Propafenone 13 0 1 1989 
Cardiovas-
cular 
63 Quinine 12 0 1 2005 
Antimicro-
bial 
64 Ranitidine 14 1 1 1983 
Gastroin-
testinal 
65 Rivaroxaban 17 0 0 2011 
Hematolo-
gic 







Drug Nº Ingredient * 
Number of 
Cases 
Fatalities Rechallenge Year Classification 
67 Sertraline 17 1 1 2005 CNS 
68 Sevoflurane 21 0 1 1995 CNS 
69 Stavudine 47 1 0 1994 
Antimicro-
bial 
70 Tamoxifen 30 1 0 1997 
Antineo-
plastic 
71 Terbinafine 30 0 0 1998 
Antimicro-
bial 
72 Thiabendazole 13 1 0 1967 
Antimicro-
bial 




12 0 1 1965 CNS 
75 Voriconazole 23 0 0 2002 
Antimicro-
bial 




* Alternative names are given in parentheses. 








APPENDIX D  
Open Data Kit Form for the electronic data capture form – survey 
TBDM Project ODK Form - survey 
   
     
type name label relevant constraint 
start start    
select_one 
yes_no 
case Is it a case?   
text name Name of patient   
date  d_birth Date of birth   
select_one 
male_female 
sex Sex   
integer med_rec  Medical record number   
integer sinan SINAN number   
date d_dili Date of DILI dx ${case} = 'yes'  
date  d_sitetb SITETB notification date ${case} = 'yes'  
select_multiple 
tb_clinic 
tb_clin Name of TB clinic   
select_one 
yes_no 
ptb Pulmonary TB?   
select_one 
yes_no 
eptb Extra pulmonary?   
text tb_site TB site ${eptb} = 'yes'  
select_one 
yes_no 
ext_tb Extensive TB?   
select_multiple 
tb_dx 
tb_dx Type of TB dx   
date  d_rhze  Date of start of RHZE   
select_multiple 
dm 
dm Has DM?   
select_multiple 
dm_dx 
dm_dx  Type of DM dx ${dm} = 'yes'  
select_multiple 
hz_drk 
hz_drk Hazardous drinking?   
select_multiple 
hiv 
hiv HIV infection?    
select_multiple 
hcv 
hcv Chronic hep C infection?   
select_multiple 
hbv 







text drugs Which drugs? ${hpx_dr} = 'yes'  
select_multiple 
oliv_dis 
oliv_dis Other liver diseases?   
text dis_name Which diseases? ${oliv_dis} = 'yes'  





Open Data Kit Form for the electronic data capture form – choices 
TBDM Project ODK Form - choices  
list name name label 
male_female 1 Male 
male_female 2 Female 
tb_clinic 1 CRTB Centro 
tb_clinic 2 CRTB Navegantes 
tb_clinic 3 CRTB Vila Comerciários 
tb_clinic 4 CRTB Bom Jesus 
tb_clinic 5 Hospital Sanatório Partenon 
yes_no yes Yes 
yes_no no No 
tb_dx 1 Smear positive 
tb_dx 2 Culture positive 
tb_dx 3 PCR/GeneXpert 
tb_dx 4 Not confirmed 
dm yes Yes 
dm no No 
dm 9 unknown  
dm_dx 1 1.a. 
dm_dx 2 1.b. 
dm_dx 3 1.c. 
dm_dx 4 1.d. 
dm_dx 5 2.a. 
dm_dx 6 2.b. 
hz_drk yes Yes 
hz_drk no No 
hz_drk 9 unknown  
hiv yes Yes 
hiv no No 
hiv 9 unknown  
hcv yes Yes 
hcv no No 
hcv 9 unknown  
hbv yes Yes 
hbv no No 
hbv 9 unknown  
hpx_dr yes Yes 
hpx_dr no No 
hpx_dr 9 unknown  
oliv_dis yes Yes 
oliv_dis no No 


































Local Authorization Term from the General Coordination of Health Surveillance – Porto 





APPENDIX I    
Local Authorization Term from the General Coordination of Specialized Care - Porto 






Table J1. Hepatotoxic drugs taken concomitantly by 402 (50.8%) patients 
Drug name Frequency % 
Omeprazole 118 29.4 
Efavirenz 88 21.9 
Sulfamethoxazole with Trimethoprim 80 19.9 
Amoxicillin with or without clavulanate 49 12.2 
Metformin 33 8.2 
Azithromycin 28 7.0 
Zidovudine 28 7.0 
Enalapril 24 6.0 
Ibuprofen 24 6.0 
Valproic acid 24 6.0 
Fluconazole 22 5.5 
Simvastatin 18 4.5 
Captopril 18 4.5 
Amitriptyline 17 4.2 
Chlorpromazine 13 3.2 
Phenobarbital 12 3.0 
Carbamazepine 10 2.5 
Contraceptives 10 2.5 
Clindamycin 9 2.2 
Haloperidol 9 2.2 
Glibenclamide 8 2.0 
Allopurinol 7 1.7 
Ciprofloxacin 7 1.7 
Imipramine 7 1.7 
Phenytoin 7 1.7 
Methotrexate 5 1.2 
Sertraline 5 1.2 
Azathioprine 4 1.0 
Ranitidine 4 1.0 
Sulfadiazine 4 1.0 
Ceftriaxone 3 0.7 
Clopidogrel 3 0.7 
Levofloxacin 3 0.7 
Nitrofurantoin 3 0.7 
Paroxetine 3 0.7 
Atorvastatin 2 0.5 
Diclofenac 2 0.5 
Hydralazine 2 0.5 
Infliximab 2 0.5 





Naproxen 2 0.5 
Rosuvastatin 2 0.5 
Sulfasalazine 2 0.5 
Ceftazidime 1 0.2 
Clozapine 1 0.2 
Duloxetine 1 0.2 
Ganciclovir 1 0.2 
Interferon 1 0.2 
Itolizumab 1 0.2 
Ketoconazole 1 0.2 
Lamotrigine 1 0.2 
Leflunomide 1 0.2 
Methimazole 1 0.2 
Olanzapine 1 0.2 
Progestogens 1 0.2 
Estrogens 1 0.2 





















Table K1. Relationship between power and sample size for a range of effect sizes 
Case:control 
ratio 













1:1 80 1.96 6.8 12.5 420 420 
1:1 90 1.96 6.8 12.5 563 563 
1:1 80 1.97 6.8 12.6 413 413 
1:1 90 1.97 6.8 12.6 553 553 
1:1 80 1.98 6.8 12.6 406 406 
1:1 90 1.98 6.8 12.6 544 544 
1:2 80 1.96 6.8 12.5 287 574 
1:2 90 1.96 6.8 12.5 384 768 
1:2 80 1.97 6.8 12.6 282 564 
1:2 90 1.97 6.8 12.6 378 755 
1:2 80 1.98 6.8 12.6 277 554 
1:2 90 1.98 6.8 12.6 371 742 
1:3 80 1.96 6.8 12.5 243 727 
1:3 90 1.96 6.8 12.5 325 973 
1:3 80 1.97 6.8 12.6 238 714 
1:3 90 1.97 6.8 12.6 319 956 
1:3 80 1.98 6.8 12.6 234 702 
1:3 90 1.98 6.8 12.6 313 939 
1:4 80 1.96 6.8 12.5 220 880 
1:4 90 1.96 6.8 12.5 295 1,178 
1:4 80 1.97 6.8 12.6 216 864 
1:4 90 1.97 6.8 12.6 290 1,157 
1:4 80 1.98 6.8 12.6 213 849 
1:4 90 1.98 6.8 12.6 284 1,136 
1:1 80 1.96 10 17.9 304 304 
1:1 90 1.96 10 17.9 406 406 
1:1 80 1.97 10 18.0 299 299 
1:1 90 1.97 10 18.8 400 400 
1:1 80 1.98 10 18.0 294 294 
1:1 90 1.98 10 18.0 393 393 
1:2 80 1.96 10 17.9 210 419 
1:2 90 1.96 10 17.9 280 560 
1:2 80 1.97 10 18.0 206 411 
1:2 90 1.97 10 18.0 276 551 
1:2 80 1.98 10 18.0 202 404 
1:2 90 1.98 10 18.0 271 541 
1:3 80 1.96 10 17.9 178 533 
1:3 90 1.96 10 17.9 238 713 





1:3 90 1.97 10 18.0 234 701 
1:3 80 1.98 10 18.0 172 515 
1:3 90 1.98 10 18.0 230 689 
1:4 80 1.96 10 17.9 162 647 
1:4 90 1.96 10 17.9 217 866 
1:4 80 1.97 10 18.0 159 636 
1:4 90 1.97 10 18.0 213 851 
1:4 80 1.98 10 18.0 156 624 
1:4 90 1.98 10 18.0 209 836 




















Integrating Statement for the DrPH Course 2011 
 
    The Doctor of Public Health (DrPH) programme of the London School of Hygiene and Tropical 
Medicine aims to provide doctoral level training for future leaders in public health practice in high 
level skills through a combination of two taught courses - “Evidence Based Public Health Policy and 
Practice” (EBPHP) and “Leadership, Management and Professional Development” (LMPD); an 
Organizational and Policy Analysis (OPA) project; and a research thesis. The purpose of these three 
components is to provide the necessary knowledge and experience, as well as hone technical skills 
for an effective public health leadership.     
     The “Leadership, Management and Professional Development” module, as it was called back in 
2011, explores management and organizational theories and how this could be applied in the 
student's own professional practice as a health manager. The course aimed at the students 
considering the application of these theories in public health organizations and their own 
management practice in a critical way, while developing a deeper understanding of themselves as 
managers and leaders in public health.  There were also discussions on power and politics within 
and between those organizations and its reflections on decision-making.  Not being a health 
manager myself, some aspects of it were quite challenging to me, such as the professional jargon 
and my lack of experience in the field, but eventually I learned a whole new set of practical skills and 
knowledge, particularly in terms of professional relationships, the way people work in organizations 
and behave as individuals and as teams. Skilful, open minded and inspiring leadership and 
management are essential for the delivery of good quality health services, whether they belong to 
a governmental public health service, an NGO or the private sector.  
    There was a three-day retreat focusing on personal professional development in which we were 
able to enhance awareness about ourselves as managers and leaders. It was a more personal 
element of the module, providing the opportunity for the students to interact with each other.  The 
LMPD module focus on a critical approach to management theories and concepts while stimulating 
the student to measure them against their own experience and perceptions of the public health 
environment.  
    There was one assignment for this module, a strategic analysis of a public health organization 





assessed the ability of our busiest public trauma hospital in Porto Alegre to prepare to provide 
emergency care for the participants of the 2014 World Cup.     
    The other taught module was then called “Evidence Based Public Health Policy and Practice”.  
Leadership in public health requires skills concerned with, on the one side, health management and 
leadership and on the other, the devising and shaping of public health policies and their 
implementation. It is necessary to locate, assess, synthesize and present the evidence, in order to 
use evidence-based information to influence public health policy and thus improve public health 
outcomes in a diverse range of settings. The dynamics of the relationship between the academic 
world, where evidence is generated, and that of policy and practice, is crucial. There is a wide range 
of stakeholders in the health care environment. Many actors such as scientists and academics, 
interest groups, policy makers and politicians are all involved in the policy process, participating in 
the way evidence is used in government health decision making.    
    There were two assignments for this module: an influencing and knowledge transfer strategy, to 
be submitted to the Brazilian Thoracic Association TB Committee, aiming to place the issue of 
homeless TB in the Ministry of Health agenda; and a systematic review on the influence of marketing 
of alcohol on alcohol use.  
     
    The OPA Project 
    Successful public health management and leadership requires a thorough understanding of the 
organization and management of institutions. It is essential to understand the ways it can promote 
and support or hinder the development of effective policy and practice. The OPA project involves 
the observation of the daily work of a public health organization (which can be a public, non-profit 
or private institution) engaged in public health practice, focusing on how it works and endeavours 
to achieve its goals in the relevant policy environment. The student is also expected to reveal not 
only positive but negative aspects about the chosen organization and present a constructive critique 
of the way the organization functions and relates with other policy actors. They should also provide 
advice to the organization in the form of a management consultant’s report. It should be evidence 
based and the student should use knowledge acquired from the taught courses: management 
theories and analytical frameworks (organizational behavioural theories, for instance) and/or policy 





    The purpose of the OPA project is to understand how public health organizations function to 
influence public health policy and/or deliver public health goals, drawing knowledge from the 
module sessions. As it is a qualitative research, the student needs to observe, interview staff and 
analyse qualitative data.  
    While considering my OPA, I came across a poem by a favourite poet of mine, Robert Frost, called 
“The road not taken”, which is about what may lie ahead of us when we choose the least trodden 
path. It occurred to me that the implementation process of any public health policy is never 
complete, never ceases to improve, and change is a vital aspect of problem solving, because that's 
the way with health and social environments. As a TB physician working for a TB control programme 
all my professional life, I had hoped to find a TB organization for my OPA. My supervisor introduced 
me to the “Find and Treat Project”, which is a project for diagnosing and managing TB cases in the 
London homeless population. I stayed with them for 4 months and then was able to collect all the 
necessary data for what was to be my first qualitative research. In order to do that, I took a MSc 
module, “Qualitative Methodologies”, where I acquired skills in collecting qualitative data, 
transcribing interview recordings, coding transcripts and analysing the findings. Most of DrPH 
students choose the management and leadership approach for their OPA research but, being a 
clinician, I chose to approach my analysis through a policy process angle. It was a quite new and 
challenging experience for me, which turned out to be very fruitful both professionally and 
personally.  
 
    Introducing Find &Treat: its history, mission and structure  
    There is every need for TB control programmes to strengthen their case finding strategies by 
raising awareness, promoting access to TB services, screening activities and supporting compliance 
to treatment. In 2005, the Department of Health provided funding for a mobile radiography unit 
(MXU) to screen for active TB among vulnerable populations across London, due to their extremely 
low rates of attendance to medical appointments. In a study conducted by Story et al. (1), the 
estimated prevalence of the disease was 788 per 100,000 in homeless individuals; 354 per 100,000 
in drug addicts; 208 per 100,000 in prisoners and 147.5 per 100, 000 in recent immigrants.  The MXU 
would visit hostels, drug treatment services and day centres. After a 2-year pilot phase, an 
evaluation was performed which drew attention to the fact that most of the cases that had been 





do it. Consequently, since 2007, the MXU has been greatly improved by the addition of a new set of 
professionals to address the problems of non-attendance and non-compliance to treatment. They 
are currently known as “Find and Treat”, an outreach service that aims not only at screening active 
TB among the homeless, substance abusers and prisoners, but also at supporting them throughout 
diagnostic procedures and treatment on a patient-centred case management basis. Both the 
screening unit and the case management support component are cost effective. 
    My study project aimed to explore policy implementation as a learning and evolutionary process. 
The first objective was to identify the differences between the project initially put into practice and 
the one that was currently known as “Find and Treat” when the study was conducted, back in 2012. 
The second objective was to identify and analyse the lessons learned throughout the years which 
had influenced its implementation process and modified the intended policy and study them in the 
light of policy implementation theories.  The methods used for my OPA study were mixed qualitative 
methods and involved participant observation, fieldwork notes, and semi-structured individual 
interviews with members of staff. The interviews were recorded, transcribed and later coded for 
analysis according to the policy implementation theoretical approaches concerned with learning 
and evolution. Although management and leadership theories were not the approach chosen for 
the study, the findings were also discussed in the light of the organizational context.  
    In closing, the OPA project concluded that “Find and Treat” is flexible and innovative, with a 
progressive model of collaborative working which is the best way to achieve its outcomes. 
Implementation is a dynamic and evolutionary process; learning is better experienced as a 
continuous process and experimentation is a risk worth taking. Like the poem. 
 
    The DrPH Thesis 
    Public health leaders are involved in commissioning research and they should develop skills in 
applying research that is relevant to the needs of policy and practice, while providing reliable and 
robust findings. Both modules contribute to those skills in conducting research with rigorous 
scientific methods. First, by appraising adequately the quality of existing research so that students 
could choose their study designs for their future projects and better develop their research 
questions; second, by learning literature search skills and conducting systematic reviews.   





first research project was a retrospective cohort study on the incident risk of progression to TB in 
immigrants to the United Kingdom with fibrotic lesions on their chest X-rays. Due to 
unsurmountable difficulties concerning access to the image database from Public Health England, 
the project had to be cancelled. My present research has questions that are concerned with practical 
aspects relevant to any TB control programme in practice. It is foremost an epidemiological (but also 
clinical) study on risk factors for drug induced liver injury due to TB drugs among patients with 




1. Story A, Murad S, Roberts W, Verheyen M, Hayward AC. Tuberculosis in London: the importance 
of homelessness, problem drug use and prison. Thorax.2007;62(8):667-71.  
 
…oooOooo… 
